1
|
de Laforcade L, Bobot M, Boffa JJ, Bovy C, Cartery C, Chauveau D, Gueutin V, Isnard-Bagnis C, Jourde Chiche N, Karras A, Meftah A, Müller C, Sié P, Stehlé T, Vrigneaud L, Vuiblet V, Guerrot D. Kidney biopsy for the diagnosis and treatment of kidney diseases. Recommendations from the French speaking Society of Nephrology (SFNDT) and French National Authority for Health (HAS) 2022. Nephrol Ther 2024; 20:61-80. [PMID: 38379375 DOI: 10.1684/ndt.2024.68] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2024]
Abstract
Kidney Biopsy (KB) is a crucial diagnostic tool in the field of renal diseases and is routinely performed in nephrology departments. A previous survey conducted by the Société Francophone de Néphrologie Dialyse Transplantation (SFNDT) revealed significant disparities in clinical practices, sometimes conflicting with the existing literature and recently published recommendations. In response, the SFNDT wished to promote the development of best practice guidelines, under the auspices of the French National Authority for Health (HAS), to establish a standardized framework for performing kidney biopsies in France.
Collapse
Affiliation(s)
- Louis de Laforcade
- Service de néphrologie-dialyse, Centre hospitalier Robert Boulin, Libourne, France
| | - Mickaël Bobot
- Centre de néphrologie et transplantation rénale, Hôpital de la Conception, AP-HM, Marseille, France
- C2VN, Aix-Marseille Université, Inserm 1263, INRAE 1260, Marseille, France
| | - Jean-Jacques Boffa
- Inserm UMRS 1155, département de néphrologie, Sorbonne université, Hôpital Tenon, AP-HP, Paris, France
| | - Christophe Bovy
- Service de néphrologie, dialyse, transplantation, CHU Liège, Belgique
| | - Claire Cartery
- Centre hospitalier de Valenciennes, service de néphrologie et médecine interne, Valencienne, France
| | - Dominique Chauveau
- Département de néphrologie et transplantation d’organes, CHU Rangueil et Université Toulouse-3, Toulouse, France
| | - Victor Gueutin
- Service de néphrologie-dialyse, Centre hospitalier Monod, Flers, France
- Service de néphrologie, dialyse et transplantation, CHU Caen, France
| | | | - Noémie Jourde Chiche
- Centre de néphrologie et transplantation rénale, Hôpital de la Conception, AP-HM, Marseille, France
- C2VN, Aix-Marseille Université, Inserm 1263, INRAE 1260, Marseille, France
| | - Alexandre Karras
- Hôpital européen Georges Pompidou, service de néphrologie, AP-HP, Université Paris Cité, Paris, France
| | - Aimèle Meftah
- Centre d’hémodialyse des Alpes, Hôpital de Manosque, Manosque France
| | - Clotilde Müller
- Service de néphrologie et dialyse, Clinique Sainte-Anne, Strasbourg, France
| | - Pierre Sié
- Laboratoire d’hématologie, Hôpital Rangueil, Toulouse France
| | - Thomas Stehlé
- Université Paris Est Créteil, Inserm U955, Institut Mondor de recherche biomédicale, Créteil, France
- Hôpitaux Universitaires Henri Mondor, AP-HP, service de néphrologie et transplantation, Fédération hospitalo-universitaire « Innovative therapy for immune disorders », Créteil, France
| | | | - Vincent Vuiblet
- Département de néphro-pathologie, Unité de pathologie, CHU Reims, France
| | - Dominique Guerrot
- Service de néphrologie-dialyse-transplantation, CHU Rouen, France ; Normandie Univ, UNIROUEN, Inserm U1096, Rouen, France
| |
Collapse
|
2
|
Geeraerts T, Guilbeau-Frugier C, Garcia C, Memier V, Raposo N, Bonneville F, Gales C, Darcourt J, Voisin S, Ribes A, Piel-Julian M, Bounes F, Albucher JF, Roux FE, Izopet J, Telmon N, Olivot JM, Sié P, Bauer J, Payrastre B, Liblau RS. Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia. Neurol Neuroimmunol Neuroinflamm 2023; 10:10/4/e200127. [PMID: 37236806 DOI: 10.1212/nxi.0000000000200127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 04/05/2023] [Indexed: 05/28/2023]
Abstract
OBJECTIVES Vaccine-induced immune thrombotic thrombocytopenia (VITT), a recently described entity characterized by thrombosis at unusual locations such as cerebral venous sinus and splanchnic vein, has been rarely described after adenoviral-encoded COVID-19 vaccines. In this study, we report the immunohistological correlates in 3 fatal cases of cerebral venous thrombosis related to VITT analyzed at an academic medical center. METHODS Detailed neuropathologic studies were performed in 3 cases of cerebral venous thrombosis related to VITT after adenoviral COVID-19 vaccination. RESULTS Autopsy revealed extensive cerebral vein thrombosis in all 3 cases. Polarized thrombi were observed with a high density of neutrophils in the core and a low density in the tail. Endothelial cells adjacent to the thrombus were largely destroyed. Markers of neutrophil extracellular trap and complement activation were present at the border and within the cerebral vein thrombi. SARS-CoV-2 spike protein was detected within the thrombus and in the adjacent vessel wall. DISCUSSION Data indicate that neutrophils and complement activation associated with antispike immunity triggered by the vaccine is probably involved in the disease process.
Collapse
Affiliation(s)
- Thomas Geeraerts
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Céline Guilbeau-Frugier
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Cédric Garcia
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Vincent Memier
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Nicolas Raposo
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Fabrice Bonneville
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Céline Gales
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Jean Darcourt
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Sophie Voisin
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Agnès Ribes
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Marie Piel-Julian
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Fanny Bounes
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Jean François Albucher
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Franck-Emmanuel Roux
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Jacques Izopet
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Norbert Telmon
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Jean Marc Olivot
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Pierre Sié
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Jan Bauer
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Bernard Payrastre
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France
| | - Roland S Liblau
- From the Department of Anesthesiology and Critical Care (T.G., F. Bounes); Department of Forensic Medicine (C.G.-F., C. Gales, N.T.), Toulouse University Hospital; Institute of Metabolic and Cardiovascular Diseases (C. Garcia, A.R., B.P.), Inserm UMR-1297; Hematology Laboratory (C. Garcia, V.M., S.V., A.R., P.S., B.P.); Department of Neurology (N.R., J.F.A., J.M.O.); Department of Neuroradiology (F. Bonneville, J.D.); Department of Internal Medicine (M.P.-J.); Department of Neurosurgery (F.R.); Department of Virology (J.I.), Toulouse University Hospital, France; Department of Neuroimmunology (J.B.), Center for Brain Research, Medical University of Vienna, Austria; and Department of Immunology (R.S.L.), Toulouse University Hospital, France.
| |
Collapse
|
3
|
Garcia C, Dejean S, Savy N, Bordet JC, Series J, Cadot S, Ribes A, Voisin S, Rugeri L, Payrastre B, Sié P. Multicolor flow cytometry in clinical samples for platelet signaling assessment. Res Pract Thromb Haemost 2023; 7:100180. [PMID: 37538502 PMCID: PMC10394564 DOI: 10.1016/j.rpth.2023.100180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Revised: 05/01/2023] [Accepted: 05/05/2023] [Indexed: 08/05/2023] Open
Abstract
Background Availability of multichannel cytometers and specific commercial antibodies makes flow cytometry a new option to simultaneously assess multiple intracellular platelet signaling pathways for clinical purposes, in small volume of blood or low platelet count. Objectives To describe a multicolor flow cytometry with fluorescent barcoding technique for screening signaling pathways downstream membrane receptors of major platelet agonists (adenosine diphosphate, thrombin, thromboxane, and collagen). Methods By comparison with immunoblotting, we first selected the target phosphoproteins, AKT, P38MAPK, LIMK, and SPL76; the times of stimulation; and phosphoflow barcoding conditions. We then performed a clinical study on whole blood of patients without evidence of blood platelet disorder on standard biological screening, consulting for trivial or occasionally provoked bleeds without familial antecedent (bleeding of unknown origin, n = 23) or type-1 von Willebrand disease (n = 9). In addition, we included a small group of patients with definite platelet disorders (Glanzmann thrombasthenia, δ-storage pool deficiency, and immune glycoprotein VI-related disease with granule secretion defect). Results The range, kinetics, and distribution of fluorescence intensity were established for each agonist-target protein combination. Principal component analysis indicates a correlation in response to a target phosphoprotein (AKT and P38MAPK) to different agonists but no correlation in the response of different target phosphoproteins to the same agonist. The heterogeneity of individual responses in the whole population displayed was analyzed using clustering algorithm. Patients with platelet storage pool deficiency were positioned as lowest responders on the heatmap. Conclusion In complement of functional tests, this study introduces a new approach for rapid platelet signaling profiling in clinical practice.
Collapse
Affiliation(s)
- Cedric Garcia
- CHU de Toulouse, Laboratoire d’Hématologie, Toulouse, France
- Institut des Maladies Métaboliques et Cardiovasculaires INSERM U1048, Université de Toulouse, Toulouse, France
| | - Sebastien Dejean
- Université Paul Sabatier Toulouse III, Institut de Mathématiques, CNRS UMR 5219, Toulouse, France
| | - Nicolas Savy
- Université Paul Sabatier Toulouse III, Institut de Mathématiques, CNRS UMR 5219, Toulouse, France
| | - Jean-Claude Bordet
- Laboratoire d’Hématologie, Hospices Civiles de Lyon, Lyon, France
- EA 4609-Hémostase et Cancer, Université Claude Bernard Lyon 1, Lyon, France
| | - Jennifer Series
- Institut des Maladies Métaboliques et Cardiovasculaires INSERM U1048, Université de Toulouse, Toulouse, France
| | - Sarah Cadot
- Institut des Maladies Métaboliques et Cardiovasculaires INSERM U1048, Université de Toulouse, Toulouse, France
| | - Agnès Ribes
- CHU de Toulouse, Laboratoire d’Hématologie, Toulouse, France
- Institut des Maladies Métaboliques et Cardiovasculaires INSERM U1048, Université de Toulouse, Toulouse, France
- Faculté de Médecine, Université Paul Sabatier Toulouse III, Toulouse, France
| | - Sophie Voisin
- CHU de Toulouse, Laboratoire d’Hématologie, Toulouse, France
| | - Lucia Rugeri
- Laboratoire d’Hématologie, Hospices Civiles de Lyon, Lyon, France
- Hospices Civils de Lyon, Unité d’Hémostase clinique, Bron, France
| | - Bernard Payrastre
- CHU de Toulouse, Laboratoire d’Hématologie, Toulouse, France
- Institut des Maladies Métaboliques et Cardiovasculaires INSERM U1048, Université de Toulouse, Toulouse, France
- Faculté de Médecine, Université Paul Sabatier Toulouse III, Toulouse, France
| | - Pierre Sié
- CHU de Toulouse, Laboratoire d’Hématologie, Toulouse, France
- Institut des Maladies Métaboliques et Cardiovasculaires INSERM U1048, Université de Toulouse, Toulouse, France
- Université Paul Sabatier Toulouse III, Faculté de Pharmacie, Toulouse, France
| |
Collapse
|
4
|
Douxfils J, Favresse J, Dogné JM, Lecompte T, Susen S, Cordonnier C, Lebreton A, Gosselin R, Sié P, Pernod G, Gruel Y, Nguyen P, Vayne C, Mullier F. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res 2021; 203:163-171. [PMID: 34029848 PMCID: PMC8123522 DOI: 10.1016/j.thromres.2021.05.010] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2021] [Revised: 05/07/2021] [Accepted: 05/08/2021] [Indexed: 01/17/2023]
Abstract
As of 4 April 2021, a total of 169 cases of cerebral venous sinus thrombosis (CVST) and 53 cases of splanchnic vein thrombosis were reported to EudraVigilance among around 34 million people vaccinated in the European Economic Area and United Kingdom with COVID-19 Vaccine AstraZeneca, a chimpanzee adenoviral vector (ChAdOx1) encoding the spike protein antigen of the SARS-CoV-2 virus. The first report of the European Medicines Agency gathering data on 20 million people vaccinated with Vaxzevria® in the UK and the EEA concluded that the number of post-vaccination cases with thromboembolic events as a whole reported to EudraVigilance in relation to the number of people vaccinated was lower than the estimated rate of such events in the general population. However, the EMA's Pharmacovigilance Risk Assessment Committee concluded that unusual thromboses with low blood platelets should be listed as very rare side effects of Vaxzevria®, pointing to a possible link. The same issue was identified with the COVID-19 Vaccine Janssen (Ad26.COV2.S). Currently, there is still a sharp contrast between the clinical or experimental data reported in the literature on COVID-19 and the scarcity of data on the unusual thrombotic events observed after the vaccination with these vaccines. Different hypotheses might support these observations and should trigger further in vitro and ex vivo investigations. Specialized studies were needed to fully understand the potential relationship between vaccination and possible risk factors in order to implement risk minimization strategies.
Collapse
Affiliation(s)
- Jonathan Douxfils
- University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium; QUALIblood s.a., Namur, Belgium.
| | - Julien Favresse
- University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium; Clinique Saint-Luc Bouge, Department of Laboratory Medicine, Bouge, Belgium
| | - Jean-Michel Dogné
- University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium
| | - Thomas Lecompte
- Départements de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland
| | - Sophie Susen
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Charlotte Cordonnier
- Univ Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France
| | - Aurélien Lebreton
- Service d'hématologie biologique, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Robert Gosselin
- University of California, Davis Health System, Thrombosis and Hemostasis Center, Sacramento, United States
| | - Pierre Sié
- University Paul Sabatier, CHU of Toulouse, Laboratory of Hematology, F-31069 Toulouse, France
| | - Gilles Pernod
- CHU Grenoble Alpes, Department of Vascular Medicine, CNRS/TIMC-IMAG UMR 5525/Themas, Grenoble, France
| | - Yves Gruel
- University of Tours, EA7501 GICC, CHRU de Tours, Department of Haemostasis, Tours, France
| | | | - Caroline Vayne
- University of Tours, EA7501 GICC, CHRU de Tours, Department of Haemostasis, Tours, France
| | - François Mullier
- CHU UCL Namur, Université catholique de Louvain, Hematology Laboratory, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Yvoir, Belgium
| |
Collapse
|
5
|
Egot M, Lasne D, Poirault-Chassac S, Mirault T, Pidard D, Dreano E, Elie C, Gandrille S, Marchelli A, Baruch D, Rendu J, Fauré J, Flaujac C, Gratacap MP, Sié P, Gaussem P, Salomon R, Baujat G, Bachelot-Loza C. Role of oculocerebrorenal syndrome of Lowe (OCRL) protein in megakaryocyte maturation, platelet production and functions: a study in patients with Lowe syndrome. Br J Haematol 2021; 192:909-921. [PMID: 33528045 DOI: 10.1111/bjh.17346] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 12/16/2020] [Accepted: 01/03/2021] [Indexed: 11/29/2022]
Abstract
Lowe syndrome (LS) is an oculocerebrorenal syndrome of Lowe (OCRL1) genetic disorder resulting in a defect of the OCRL protein, a phosphatidylinositol-4,5-bisphosphate 5-phosphatase containing various domains including a Rho GTPase-activating protein (RhoGAP) homology domain catalytically inactive. We previously reported surgery-associated bleeding in patients with LS, suggestive of platelet dysfunction, accompanied with a mild thrombocytopenia in several patients. To decipher the role of OCRL in platelet functions and in megakaryocyte (MK) maturation, we conducted a case-control study on 15 patients with LS (NCT01314560). While all had a drastically reduced expression of OCRL, this deficiency did not affect platelet aggregability, but resulted in delayed thrombus formation on collagen under flow conditions, defective platelet spreading on fibrinogen and impaired clot retraction. We evidenced alterations of the myosin light chain phosphorylation (P-MLC), with defective Rac1 activity and, inversely, elevated active RhoA. Altered cytoskeleton dynamics was also observed in cultured patient MKs showing deficient proplatelet extension with increased P-MLC that was confirmed using control MKs transfected with OCRL-specific small interfering(si)RNA (siOCRL). Patients with LS also had an increased proportion of circulating barbell-shaped proplatelets. Our present study establishes that a deficiency of the OCRL protein results in a defective actomyosin cytoskeleton reorganisation in both MKs and platelets, altering both thrombopoiesis and some platelet responses to activation necessary to ensure haemostasis.
Collapse
Affiliation(s)
- Marion Egot
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - Dominique Lasne
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France.,AP-HP, Laboratoire d'Hématologie, Hôpital Necker-Enfants Malades, Paris, France
| | - Sonia Poirault-Chassac
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - Tristan Mirault
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France.,AP-HP, Service de Médecine Vasculaire, Hôpital Européen Georges-Pompidou, Paris, France
| | - Dominique Pidard
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - Elise Dreano
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - Caroline Elie
- AP-HP, Unité de Recherche Clinique, Hôpital Necker-Enfants Malades, Paris, France
| | - Sophie Gandrille
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - Aurore Marchelli
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - Dominique Baruch
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France
| | - John Rendu
- University Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France
| | - Julien Fauré
- University Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France
| | - Claire Flaujac
- Centre hospitalier de Versailles, André Mignot, Service de Biologie Médicale, Secteur Hémostase, Le Chesnay, France
| | - Marie-Pierre Gratacap
- INSERM U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), CHU-Rangueil, Toulouse, France
| | - Pierre Sié
- INSERM U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), CHU-Rangueil, Toulouse, France.,CHU de Toulouse, Laboratoire d'Hématologie, Toulouse, France
| | - Pascale Gaussem
- Université de Paris, Innovations Thérapeutiques en Hémostase, Paris, INSERM U1140, France.,AP-HP, Service d'Hématologie Biologique, Hôpital Européen Georges Pompidou, Paris, France
| | - Rémi Salomon
- AP-HP, Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, INSERM U983, Paris, France
| | - Geneviève Baujat
- AP-HP, Service de Génétique, Institut Imagine, Hôpital Necker-Enfants Malades, Paris, France
| | | |
Collapse
|
6
|
Series J, Ribes A, Garcia C, Souleyreau P, Bauters A, Morschhauser F, Jürgensmeier JM, Sié P, Ysebaert L, Payrastre B. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. J Thromb Haemost 2020; 18:3336-3351. [PMID: 32926549 DOI: 10.1111/jth.15098] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 07/25/2020] [Accepted: 08/31/2020] [Indexed: 12/21/2022]
Abstract
BACKGROUND Inhibitors of tyrosine kinases downstream of the B-cell receptor, such as Bruton's tyrosine kinase (Btk) or Spleen tyrosine kinase (Syk), used alone or in combination are new therapeutic options in the treatment of B-cell malignancies. A challenge in the development of second-generation Btk inhibitors is to limit their side effects such as the increased bleeding risk. Considering the pivotal role of Syk in immunoreceptor tyrosine-based activation motif mediated platelet signaling, the impact of inhibiting this kinase on platelet functions is also worth analyzing. OBJECTIVES We investigated the effect of a novel Btk inhibitor, tirabrutinib, and a Syk inhibitor, entospletinib, alone and in combination on platelet signaling and functions in vitro and ex vivo. METHODS Platelet aggregation, secretion, and signaling responses as well as thrombus growth under flow were analyzed in the presence of the inhibitors alone or in combination in vitro, at clinically relevant doses, and ex vivo in patients treated with these inhibitors in the context of a phase I trial. RESULTS Although tirabrutinib alone had modest effects on platelet activation in vitro and ex vivo, entospletinib alone efficiently inhibited washed platelet aggregation in response to collagen. However, entospletinib weakly affected platelet activation in platelet-rich plasma, in whole blood and ex vivo. Importantly, the combination of tirabrutinib and entospletinib induced a significant decrease in platelet response to collagen in vitro and ex vivo correlating with mild bleedings reported in some of the treated patients. CONCLUSION These new results should contribute to improve the safety of these targeted therapies.
Collapse
Affiliation(s)
- Jennifer Series
- Inserm, U1048, Université Toulouse 3, I2MC, Toulouse Cedex 04, France
- Laboratoire d'Hématologie CHU de Toulouse, Toulouse Cedex 04, France
| | - Agnès Ribes
- Inserm, U1048, Université Toulouse 3, I2MC, Toulouse Cedex 04, France
- Laboratoire d'Hématologie CHU de Toulouse, Toulouse Cedex 04, France
| | - Cédric Garcia
- Inserm, U1048, Université Toulouse 3, I2MC, Toulouse Cedex 04, France
- Laboratoire d'Hématologie CHU de Toulouse, Toulouse Cedex 04, France
| | - Pierre Souleyreau
- Laboratoire d'Hématologie CHU de Toulouse, Toulouse Cedex 04, France
| | - Anne Bauters
- Institut d'hématologie-transfusion, Laboratoire d'hémostase, CHU Lille, Lille, France
| | | | | | - Pierre Sié
- Inserm, U1048, Université Toulouse 3, I2MC, Toulouse Cedex 04, France
- Laboratoire d'Hématologie CHU de Toulouse, Toulouse Cedex 04, France
| | - Loïc Ysebaert
- Service d'Hématologie IUCT-oncopôle, Toulouse Cedex 09, France
| | - Bernard Payrastre
- Inserm, U1048, Université Toulouse 3, I2MC, Toulouse Cedex 04, France
- Laboratoire d'Hématologie CHU de Toulouse, Toulouse Cedex 04, France
| |
Collapse
|
7
|
Ribes A, Vardon-Bounes F, Mémier V, Poette M, Au-Duong J, Garcia C, Minville V, Sié P, Bura-Rivière A, Voisin S, Payrastre B. Thromboembolic events and Covid-19. Adv Biol Regul 2020; 77:100735. [PMID: 32773098 PMCID: PMC7833411 DOI: 10.1016/j.jbior.2020.100735] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 06/04/2020] [Indexed: 01/08/2023]
Abstract
The novel Corona virus infection (Covid-19) first identified in China in December 2019 has rapidly progressed in pandemic leading to significant mortality and unprecedented challenge for healthcare systems. Although the clinical spectrum of Covid-19 is variable, acute respiratory failure and systemic coagulopathy are common in severe Covid-19 patients. Lung is an important target of the SARS-CoV-2 virus causing eventually acute respiratory distress syndrome associated to a thromboinflammatory state. The cytokinic storm, thromboinflammation and pulmonary tropism are the bedrock of tissue lesions responsible for acute respiratory failure and for prolonged infection that may lead to multiple organ failure and death. The thrombogenicity of this infectious disease is illustrated by the high frequency of thromboembolic events observed even in Covid-19 patients treated with anticoagulation. Increased D-Dimers, a biomarker reflecting activation of hemostasis and fibrinolysis, and low platelet count (thrombocytopenia) are associated with higher mortality in Covid-19 patients. In this review, we will summarize our current knowledge on the thromboembolic manifestations, the disturbed hemostatic parameters, and the thromboinflammatory conditions associated to Covid-19 and we will discuss the modalities of anticoagulant treatment or other potential antithrombotic options.
Collapse
Affiliation(s)
- Agnès Ribes
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France
| | - Fanny Vardon-Bounes
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France
| | - Vincent Mémier
- Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France
| | - Michael Poette
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France
| | - Jonathan Au-Duong
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France
| | - Cédric Garcia
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France
| | - Vincent Minville
- Pôle Anesthésie-Réanimation, CHU de Toulouse, 31059, Toulouse, France
| | - Pierre Sié
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France
| | | | - Sophie Voisin
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France
| | - Bernard Payrastre
- Inserm U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024, Toulouse Cedex 03, France; Laboratoire d'Hématologie, CHU de Toulouse, 31059, Toulouse, France.
| |
Collapse
|
8
|
Alessi MC, Sié P, Payrastre B. Strengths and Weaknesses of Light Transmission Aggregometry in Diagnosing Hereditary Platelet Function Disorders. J Clin Med 2020; 9:jcm9030763. [PMID: 32178287 PMCID: PMC7141357 DOI: 10.3390/jcm9030763] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 02/17/2020] [Accepted: 03/03/2020] [Indexed: 12/15/2022] Open
Abstract
Hereditary defects in platelet function are responsible for sometimes severe mucocutaneous hemorrhages. They are a heterogeneous group of abnormalities whose first-line diagnosis typically involves interpreting the results of in vitro light transmission aggregometry (LTA) traces. Interpretation of LTA is challenging. LTA is usually performed in specialized laboratories with expertise in platelet pathophysiology. This review updates knowledge on LTA, describing the various platelet aggregation profiles typical of hereditary platelet disorders to guide the physician in the diagnosis of functional platelet disorders.
Collapse
Affiliation(s)
- Marie-Christine Alessi
- Aix Marseille Univ, Inserm, Inrae, C2VN, 13385 Marseille CEDEX, France
- Correspondence: ; Tel.: +33-4-91-32-45-06
| | - Pierre Sié
- CHU de Toulouse, Laboratoire d’Hématologie, 31059 Toulouse CEDEX, France;
| | - Bernard Payrastre
- Inserm U1048, I2MC et Université Paul Sabatier, 31024 Toulouse CEDEX, France;
| |
Collapse
|
9
|
Dumonteil N, Levade M, Garcia C, Lhermusier T, Series J, Le Faouder P, Marcheix B, Payrastre B, Carrié D, Sié P. Platelet Activation Is Limited during Transcatheter Aortic Valve Implantation in Patients on Aspirin Monotherapy and without per Procedural Clinical Complications. TH Open 2019; 3:e146-e152. [PMID: 31259296 PMCID: PMC6598084 DOI: 10.1055/s-0039-1692142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Accepted: 04/18/2019] [Indexed: 11/25/2022] Open
Abstract
Transcatheter aortic valve implantation (TAVI) is an established treatment option for symptomatic patients with severe aortic valve stenosis (AS). During and early after the procedure, both ischemic events (predominantly stroke) and bleedings remain prevalent. The optimal antithrombotic regimen is still debated. Single- versus dual-antiplatelet therapy is associated with a lower rate of severe bleeding, without difference in thrombotic complications. Although platelets have been empirically targeted, little is known on their contribution to these events primarily related to embolization of thrombotic material and tissue-derived debris from the wounded aortic valve and large vessels. The objective of this study was to assess local platelet activation in blood sampled in the ascending aorta immediately before and within minutes postimplantation. A series of 18 patients with AS on monotherapy with aspirin successfully underwent TAVI with the self-expandable Medtronic CoreValve by transfemoral route. No clinical thrombotic complication occurred at 30-day follow-up. Compared with patients with stable coronary artery disease unscathed of AS and similarly treated by low-dose aspirin, AS patients displayed a chronic state of platelet activation before TAVI, assessed in venous blood using various biomarkers. However, per procedure, in aortic blood, no change occurred between the two time points in the plasma levels of serotonin or 12-lipoxgenase products, or membrane exposure of granule markers CD62-P and CD63. Our results suggest that local acute platelet activation is limited during TAVI on monotherapy with aspirin.
Collapse
Affiliation(s)
- Nicolas Dumonteil
- Pôle Cardiovasculaire et Métabolique, Hôpital Rangueil, Toulouse, France
| | - Marie Levade
- INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Cédric Garcia
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Thibault Lhermusier
- Pôle Cardiovasculaire et Métabolique, Hôpital Rangueil, Toulouse, France
- INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France
| | - Jennifer Series
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Pauline Le Faouder
- MetaToul-Lipidomique, INSERM U1048 and Université Paul Sabatier Toulouse 3, Toulouse, France
| | - Bertrand Marcheix
- Pôle Cardiovasculaire et Métabolique, Hôpital Rangueil, Toulouse, France
| | - Bernard Payrastre
- INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Didier Carrié
- Pôle Cardiovasculaire et Métabolique, Hôpital Rangueil, Toulouse, France
- INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France
| | - Pierre Sié
- INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| |
Collapse
|
10
|
Series J, Garcia C, Levade M, Viaud J, Sié P, Ysebaert L, Payrastre B. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica 2019; 104:2292-2299. [PMID: 30819914 PMCID: PMC6821604 DOI: 10.3324/haematol.2018.207183] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Accepted: 02/28/2019] [Indexed: 12/24/2022] Open
Abstract
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two groups in the healthy population characterized by low or high sensitivity to ibrutinib in vitro. Inhibition of drug efflux pumps induced a shift from ibrutinib low-sensitive platelets to high-sensitive ones. At a clinically relevant dose, acalabrutinib, a second-generation BTK inhibitor, did not affect maximal collagen-induced platelet aggregation in the ibrutinib low-sensitive group but did inhibit aggregation in a small fraction of the ibrutinib high-sensitive group. Consistently, acalabrutinib delayed aggregation, particularly in the ibrutinib high-sensitive group. In chronic lymphocytic leukemia patients, acalabrutinib inhibited maximal platelet aggregation only in the ibrutinib high-sensitive group. Acalabrutinib inhibited collagen-induced tyrosine-753 phosphorylation of phospholipase Cγ2 in both groups, but, in contrast to ibrutinib, did not affect Src-family kinases. Acalabrutinib affected thrombus growth under flow only in the ibrutinib high-sensitive group and potentiated the effect of cyclooxygenase and P2Y12 receptor blockers in both groups. Since the better profile of acalabrutinib was observed mainly in the ibrutinib low-sensitive group, replacement therapy in patients may not systematically reduce the risk of bleeding.
Collapse
Affiliation(s)
- Jennifer Series
- Inserm, U1048 and Université Toulouse 3, Toulouse Cedex 04.,Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 04
| | - Cédric Garcia
- Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 04
| | - Marie Levade
- Inserm, U1048 and Université Toulouse 3, Toulouse Cedex 04.,Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 04
| | - Julien Viaud
- Inserm, U1048 and Université Toulouse 3, Toulouse Cedex 04
| | - Pierre Sié
- Inserm, U1048 and Université Toulouse 3, Toulouse Cedex 04.,Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 04
| | - Loïc Ysebaert
- Service d'Hématologie IUCT-Oncopôle, Toulouse Cedex 09, France
| | - Bernard Payrastre
- Inserm, U1048 and Université Toulouse 3, Toulouse Cedex 04 .,Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 04
| |
Collapse
|
11
|
Vardon Bounes F, Mémier V, Marcaud M, Jacquemin A, Hamzeh-Cognasse H, Garcia C, Series J, Sié P, Minville V, Gratacap MP, Payrastre B. Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis. Sci Rep 2018; 8:13536. [PMID: 30201980 PMCID: PMC6131186 DOI: 10.1038/s41598-018-31910-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Accepted: 08/24/2018] [Indexed: 02/07/2023] Open
Abstract
Sepsis is associated with thrombocytopenia and microvascular thrombosis. Studies have described platelets implication in this pathology but their kinetics of activation and behavior remain poorly known. We show in a mouse model of peritonitis, the appearance of platelet-rich thrombi in organ microvessels and organ damage. Complementary methods are necessary to characterize platelet activation during sepsis as circulating soluble markers and platelet-monocyte aggregates revealed early platelet activation, while surface activation markers were detected at later stage. A microfluidic based ex-vivo thrombosis assay demonstrated that platelets from septic mice have a prothrombotic behavior at shear rate encountered in microvessels. Interestingly, we found that even though phosphoinositide-3-kinase β-deficient platelet mice formed less thrombi in liver microcirculation, peritoneal sepsis activates a platelet alternative pathway to compensate the otherwise mandatory role of this lipid-kinase to form stable thrombi at high shear rate. Platelets are rapidly activated during sepsis. Thrombocytopenia can be attributed in part to platelet-rich thrombi formation in capillaries and platelet-leukocytes interactions. Platelets from septic mice have a prothrombotic phenotype at a shear rate encountered in arterioles. Further studies are necessary to unravel molecular mechanisms leading to this prothrombotic state of platelets in order to guide the development of future treatments of polymicrobial sepsis.
Collapse
Affiliation(s)
- Fanny Vardon Bounes
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France.
- Anesthesiology and Critical Care Unit, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France.
| | - Vincent Mémier
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
- Haematology laboratory, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| | - Marina Marcaud
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
| | - Aemilia Jacquemin
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
- Anesthesiology and Critical Care Unit, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| | | | - Cédric Garcia
- Haematology laboratory, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| | - Jennifer Series
- Haematology laboratory, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| | - Pierre Sié
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
- Haematology laboratory, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| | - Vincent Minville
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
- Anesthesiology and Critical Care Unit, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| | - Marie-Pierre Gratacap
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
| | - Bernard Payrastre
- INSERM, U1048 et Université Toulouse III, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, 31400, France
- Haematology laboratory, Centre hospitalier universitaire de Toulouse, Toulouse, 31400, France
| |
Collapse
|
12
|
Albaladejo P, Pernod G, Godier A, de Maistre E, Rosencher N, Mas JL, Fontana P, Samama CM, Steib A, Schlumberger S, Marret E, Roullet S, Susen S, Madi-Jebara S, Nguyen P, Schved JF, Bonhomme F, Sié P. Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) – September 2016. Anaesth Crit Care Pain Med 2018; 37:391-399. [DOI: 10.1016/j.accpm.2018.04.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Revised: 04/17/2018] [Accepted: 04/18/2018] [Indexed: 11/25/2022]
|
13
|
Peyrou V, Lormeau JC, Caranobe C, Gabaig AM, Crepon B, Salvin S, Houin G, Sié P, Boneu B. Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1648851] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study compares some in vivo pharmacological properties of CY 216 and of its ACLM and BCLM components having a molecular weight above and below 5.4 kDa respectively. The anti-factor Xa/anti-thrombin ratio of these compounds determined in a rabbit plasma system were 2.5 and 1.2 for CY 216 and ACLM respectively while BCLM was devoid of anti-thrombin effect. After bolus intravenous injection, continuous infusion and subcutaneous administration, the clearances of anti-factor Xa activity generated by ACLM were, on the average, 2 and 1.5 times higher than those generated by BCLM and CY 216 respectively. The clearances of the anti-thrombin activity were comparable for CY 216 and ACLM, and higher than those of the antifactor Xa activity. The duration of the antithrombotic effect was investigated in the Wessler model after a single subcutaneous injection of 1000 anti-factor Xa units of one of the compounds. Using thromboplastin as thrombogenic stimulus, the most efficient agent was ACLM and the antithrombotic activity was essentially correlated to the circulating anti-thrombin activity. Using human serum as thrombogenic stimulus, ACLM and BCLM were more efficient than CY 216 and the antithrombotic activity was mainly correlated to the anti-factor Xa activity. The ability of the 3 compounds to inhibit venous thrombosis growth was compared: they were found equipotent and the antithrombotic effect was independent of the anti-thrombin activity. The pro-haemorrhagic properties were compared in the rabbit ear model. The activity of the 3 compounds were comparable and significantly less prohaemorrhagic than unfractionated heparin. These results suggest that the haemorrhagic potential of unfractionated heparin and of LMWH is independent of the anti-thrombin and anticoagulant activity, but related to the molecular weight. These observations indicate that factor Xa inhibition is a valuable target to prevent and to treat venous thrombosis and that the anti-factor Xa activity of a low molecular weight heparin (LMWH) largely contributes to its antithrombotic effect.
Collapse
Affiliation(s)
- V Peyrou
- The Laboratoire de Recherche sur I’Hemostase et la Thrombose, Pavilion Charles Lefebvre, Hopital Purpan, Toulouse, France
| | - J C Lormeau
- Sanofi Recherche, Centre CHOAY, Gentilly, France
| | - C Caranobe
- The Laboratoire de Recherche sur I’Hemostase et la Thrombose, Pavilion Charles Lefebvre, Hopital Purpan, Toulouse, France
| | - A M Gabaig
- The Laboratoire de Recherche sur I’Hemostase et la Thrombose, Pavilion Charles Lefebvre, Hopital Purpan, Toulouse, France
| | - B Crepon
- Sanofi Recherche, Centre CHOAY, Gentilly, France
| | - S Salvin
- Unite de Pharmacocinetique, Hopital Purpan, Toulouse, France
| | - G Houin
- Unite de Pharmacocinetique, Hopital Purpan, Toulouse, France
| | - P Sié
- Laboratoire d’Hematologie, Faculte de Sciences Pharmaceutiques, Universite Paul-Sabatier, Toulouse, France
| | - B Boneu
- The Laboratoire de Recherche sur I’Hemostase et la Thrombose, Pavilion Charles Lefebvre, Hopital Purpan, Toulouse, France
| |
Collapse
|
14
|
Briant L, Caranobe C, Saivin S, Sié P, Bayrou B, Houin G, Boneu B. Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the Rabbit. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646593] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis report compares the pharmacokinetics and the bioavailabilities of the antifactor Xa and of the antifactor II a activities generated by intravenous (IV) and subcutaneous (SC) injections of increasing doses of unfractionated heparin (UH) and of a low molecular weight heparin (CY 216). Rabbits were injected with 500, 1,000, 2,500 and 5,000 antifactor Xa u/kg of both heparins and their biological activities were followed at various time intervals. After IV injection the clearance of the antifactor Xa activities was independent of the dose and the clearance of UH was significantly higher than that of CY 216; after SC injection the bioavailability estimated from the antifactor Xa effect was consistently over 100% for CY 216 while that of UH increased from 27% at the lowest dose to 93% at the highest dose. The pharmacokinetic parameters estimated by the antifactor IIa activity of UH were superimposable to those calculated with the antifactor Xa activity. For CY 216 no direct comparison between the two activities was made since the dose injected expressed in antifactor IIa units was 3.4 times lower. UH and CY 216 were therefore injected intravenously to other animals at equivalent and increasing doses expressed in antifactor IIa units (50-5,000 u/kg). The pharmacokinetic parameters calculated from the curves of the antifactor IIa activities were basically identical except at the two lower doses (50 and 100 u/kg) for which UH was cleared faster than CY 216. These results indicate that the antifactor IIa activity generated by an injection of CY 216 disappears faster than the corresponding antifactor Xa activity and therefore that the antifactor Xa/antifactor IIa activity ratio of CY 216 progressively increases after SC or IV injection.
Collapse
Affiliation(s)
- L Briant
- Laboratoire d’Hémostase, Centre de Transfusion, Toulouse, France
| | - C Caranobe
- Laboratoire d’Hémostase, Centre de Transfusion, Toulouse, France
| | - S Saivin
- Unité de Pharmacocinétique, Hôpital Purpan, Toulouse, France
| | - P Sié
- Laboratoire d’Hémostase, Centre de Transfusion, Toulouse, France
| | | | - G Houin
- Unité de Pharmacocinétique, Hôpital Purpan, Toulouse, France
| | - B Boneu
- Laboratoire d’Hémostase, Centre de Transfusion, Toulouse, France
| |
Collapse
|
15
|
Affiliation(s)
- C Caranobe
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| | - A M Gabaig
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| | - P Sié
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| | - B Boneu
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| |
Collapse
|
16
|
Cadroy Y, Caranobe C, Bernat A, Maffrand JP, Sié P, Boneu B. Antithrombotic and Bleeding Effects of a New Synthetic Direct Thrombin Inhibitor and of Standard Heparin in the Rabbit. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1645966] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study reports on (he anticoagulant, antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor (SDTI) in comparison with standard heparin (SH). The anticoagulant effect was determined with the thrombin clotting time (TCI) and the activated partial thromboplastin time (APTT). SDTI was more potent than SII in prolonging the TCT, but as potent as SH in prolonging the APTT. The antithrombotic effect was determined using a modified Wessler model in the rabbit, either 30 min after a continuous IV infusion of increasing doses or at various times after a single SC injection (20 mg/kg). After continuous IV infusion of 187 μg/kg/h of SDTI and of 60 μg/kg/h of SH, significant thrombus prevention effects were obtained (59 and 57% respectively). Increasing the dose of SDTI up to 3000 μg/kg/h did not significantly impiove the antithrombotic effect. After SC injection, a significant antihrombotic effect was observed for 12 h with SDTI but for more than 24 h with SH. The bleeding effect was studied using the rabbit ear model 15 min after a continuous infusion of 7.5 and 15 mg/kg/h: the amounts of blood loss were dose-dependent and comparable for SDTI and SH. These studies also indicated that SDTI possesses a considerable shorter half-life in comparison with SH. Accordingly, the ex vivoconcentrations generated after continuous IV infusion or SC injection of the same dose were higher for SH than for the SDTI.
Collapse
Affiliation(s)
- Y Cadroy
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - C Caranobe
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - A Bernat
- The SanofiRecherche, Toulouse, France
| | | | - P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
17
|
Caranobe C, Sié P, Fernandez F, Pris J, Moatti S, Boneu B. Abnormal Platelet Serotonin Uptake and Binding Sites in Myeloproliferative Disorders. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661099] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA simultaneous investigation of the kinetics of serotonin (5 HT) uptake and of binding sites was carried out in the platelets of normal subjects and of 10 patients affected with various types of myeloproliferative disorders (MD). The 5 HT uptake was analysed according to the Lineweaver-Burk and the Eadie-Hofstee methods. With the two methods, the patient’s platelets exhibited a dramatic reduction of the Vi max and of the Km; in some patients the Eadie-Hofstee analysis revealed that a passive diffusion phenomenon is superimposed on the active 5 HT uptake at least for the higher concentration used. The binding data were analysed with the Scatchard method. Two classes of binding sites (high affinity - low capacity, low affinity - high capacity) were found in normal subjects and patients. Pharmacological studies with imipramine, a specific inhibitor of 5 HT uptake, suggested that both the sites are involved in 5 HT uptake. The number of both binding sites was significantly decreased in patient’s platelets while the affinity constants of these binding sites were not significantly reduced in comparison with those of the control subjects. No correlations were found between Vi max, Km and the number of binding sites. These results suggest that a reduction in the number of platelet membrane acceptors for 5 HT commonly occurs in myeloproliferative disorders but does not provide a full explanation of the uptake defect.
Collapse
Affiliation(s)
- C Caranobe
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - F Fernandez
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - J Pris
- The Service d’Hématologie, Hôpital Purpan, Toulouse, France
| | - S Moatti
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
18
|
Douste-Blazy P, Sié P, Boneu B, Marco J, Eche N, Bernadet P. Exercise-Induced Platelet Activation in Myocardial Infarction Survivors with Normal Coronary Arteriogram. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661199] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryPlatelet activation may participate in the pathophysiology of myocardial infarction occurring in patients with normal coronary arteriogram. We investigated this possibility in a series of 9 such patients (group A) during a standardized bicycle excercise test as myocardial infarction had occurred in all of them during or soon after strong physical exercise. Twelve patients with effort-induced angina and coronary atherosclerosis (group B) and eleven healthy subjects (group C) served as test groups. Peripheral venous blood was collected by separate venipuncture before, at peak exercise and during recovery. As a sensitive index of activation, the shape of the circulating platelets was examined with a phase contrast microscope after instantaneous fixation of the whole blood. The percentage of non strictly disc-shaped platelets with one or more thin pseudopods was determined. Simultaneously, the plasma levels of platelet factor 4 (PF4) and of beta-thromboglobulin (β-TG) were measured. At rest, there was no significant difference in the platelet morphology nor in the plasma levels of platelet specific proteins between the three groups. During exercise, a significant change in platelet shape occurred in group A and B patients and not in the healthy subjects. This platelet activation was not related to myocardial ischemia since it occurred to a similar extent in group B patients who developed electrocardiographic changes and in group A patients who did not. There was no detectable release of platelet proteins during exercise in any group.
Collapse
Affiliation(s)
- Ph Douste-Blazy
- The Clinique Cardiologique, Hôpital Purpan, Toulouse, France
| | - P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - J Marco
- The Clinique Cardiologique, Hôpital Purpan, Toulouse, France
| | - N Eche
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - P Bernadet
- The Clinique Cardiologique, Hôpital Purpan, Toulouse, France
| |
Collapse
|
19
|
Abstract
SummaryHeparin cofactor II (HC II) is a heparin-dependent inhibitor of thrombin, distinct from antithrombin III (AT III). This study was designed to evaluate its metabolism in healthy subjects. Purified HC II was labelled with 125I by the lactoperoxidase-glucose oxidase technique. The biological activity of the HC II was unchanged after labelling as was its migratory pattern by crossed immunoelectrophoresis in the presence of heparin or dermatan sulfate.Three healthy volunteers were injected with 10 uCi and the plasma radioactivity was measured daily. The data were approximated by a sum of two exponential terms and the metabolism of HC II was described by a two compartment mamillary system.The mean values of fractional catabolic rate, intravascular fraction and half-life of the elimination phase were respectively: 0.44 d-1, 0.60 and 2.53 d. These parameters are of the same order of magnitude as those reported in the literature for AT III. The plasma HC II concentration in the 3 subjects ranged from 61 to 82 ug/ml as estimated using our purified preparation. Accordingly, the absolute catabolic rate ranged from 1.17 to 1.36 mg · kg-1 · d-1.
Collapse
Affiliation(s)
- P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - D Dopouy
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - J Pichon
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
20
|
Affiliation(s)
- P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| | - C Caranobe
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| | | | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, 31052 Toulouse Cedex, France
| |
Collapse
|
21
|
Sié P, Albarede JL, Robert M, Bouloux C, Lansen J, Chigot C, Correll S, Thouvenot JP, Boneu B. Tolerance and Biological Activity of Pentosan Polysulfate After Intramuscular or Subcutaneous Administration for Ten Days in Human Volunteers. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661453] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study reports on the tolerance and the pharmacological activity of pentosan polysulfate (PPS) administered to healthy volunteers for 10 days. Three groups of 10 subjects received either one daily injections of 100 mg of PPS by I. M. route (group I), or two daily injection of 50 mg of PPS by I. M. or S. C. route (groups II and III, respectively). In each group two random subjects received a placebo for the 10 days; on day 0, each subject was injected by a placebo. Clinical tolerance was checked by a daily physical examination; biological tolerance was assessed comparing the results of the main biochemical and haematological constants measured before starting the treatment (day 0) and 12 or 24 h after the end of the treatment (day 11). The pharmacological activity was measured on serial samples taken before treatment and between 1 and 6 h after the drug injection on days 1, 3 and 10; the results were compared to those obtained on day 0. Clinical tolerance was good. The biological side effects concern the transaminase levels and the platelet counts. An increase above the upper normal limit was observed in 18/i4 and 3/24 for alanine and aspartic transaminase respectively. The mean platelet reduction ranged between 24 and 34% according to the groups. The drug injection induced a slight Quick time (PT) prolongation, no significant alteration of factors II, VII-X, V levels and of thrombin clotting time. The activated partial thromboplastin time (APTT) was significantly prolonged and there was a weak but significant circulating anti-Xa activity. The fibrinolytic activity was enhanced without increase in the tissue plasminogen activator antigen level. These pharmacological effects were at their maximum between 2 and 4 h after the drug injection and returned to the pre-injection equilibrium between 4 and 6 h except for circulating anti-Xa activity; these effects remained unchanged all over the 10-day therapeutic period. The comparison between group I and II indicates that the PT and APTT effects are dose-dependent while the anti-Xa and the profibrinolytic effects are not; the comparison between group II and III indicates that the S. C. and I. M. route are bioequivalent.
Collapse
Affiliation(s)
- P Sié
- The Laboratoires Centraux d’Hématologie et de Biochimie II et Centre de Gériatrie, Toulouse, France
| | - J L Albarede
- The Laboratoires Centraux d’Hématologie et de Biochimie II et Centre de Gériatrie, Toulouse, France
| | - M Robert
- The Laboratoires Centraux d’Hématologie et de Biochimie II et Centre de Gériatrie, Toulouse, France
| | - C Bouloux
- The Hôpital Purpan, Toulouse, and Sanofi Recherche, Toulouse, France
| | - J Lansen
- The Hôpital Purpan, Toulouse, and Sanofi Recherche, Toulouse, France
| | - C Chigot
- The Hôpital Purpan, Toulouse, and Sanofi Recherche, Toulouse, France
| | - S Correll
- The Hôpital Purpan, Toulouse, and Sanofi Recherche, Toulouse, France
| | - J P Thouvenot
- The Laboratoires Centraux d’Hématologie et de Biochimie II et Centre de Gériatrie, Toulouse, France
| | - B Boneu
- The Laboratoires Centraux d’Hématologie et de Biochimie II et Centre de Gériatrie, Toulouse, France
| |
Collapse
|
22
|
Dol F, Sié P, Dupouy D, Boneu B. Effect of Pentosan Polysulphate Administration in Man on the Formation of Covalent Complexes Between Heparin Cofactor II and Thrombin Generated in Plasma by Contact Activation. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661670] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryAn assay for the quantification of pentosan polysulphate (PPS) in plasma is described. As PPS has been shown to potentiate thrombin inhibition by the second heparin cofactor (HC II), the principle of this assay was to measure the formation of covalent complexes between HC II and the thrombin generated in plasma after contact activation and recalcification. The complexes were quantified by using purified 125I-HC II added to the plasma as a tracer and SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The assay was sensitive to low PPS concentrations (limit of detection: 0.1 μg/ml) and therefore suitable for the measurement of PPS in plasma after its administration to man.The clearance of PPS was studied in 3 subjects receiving respectively 10, 50 and 100 mg intravenously (IV) and in 3 subjects receiving 35 mg subcutaneously (SC). PPS was still detectable 8 h after 50 and 100 mg IV and 6 h after 35 mg SC. The activated partial thromboplastin time (APTT) was, in comparison, relatively insensitive but for concentrations above 1 μg/ ml the values derived from the APTT and from the SDS-PAGE method fitted. The results were also in general agreement with those reported by McGregor et al. (5) who used a sensitive competitive binding assay. This indicates that low concentrations of PPS previously measured chemically are also pharmacologically active in plasma.
Collapse
Affiliation(s)
- F Dol
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - D Dupouy
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
23
|
Sié P, Lansen J, Lacheretz F, Verschuere B, Boneu B. Comparative Turn-Over of Heparin Cofactor II and Antithrombin III in Baboons Influence of Heparin and Pentosan Polysulfate Administration. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661672] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryHeparin and pentosan polysulfate (PPS) interact in plasma with antithrombin III (AT III) and Heparin cofactor II (HC II) respectively. To assess the influence of heparin or PPS treatment on the metabolism of their respective cofactors, we performed a double tracer study in baboons receiving heparin or PPS. Purified AT III and HC II from human plasma were labelled with 131I and 125I respectively by the lactoperoxidase-glucose oxidase technique. The tracers had unchanged biological activities, were homogenous in SDS-PAGE, migrated as native proteins by crossed immunoelectrophoresis in the presence of heparin or PPS and virtually coeluted with endogenous baboon proteins from heparin-agarose. Nine animals were randomly allocated to receive, during the metabolic study, heparin (500 IU/kg/d, n = 3), PPS (5 mg/kg,d, n = 3) or a placebo (n = 3) given in 2 daily subcutaneous injections. Heparin levels and anticoagulant effects were similar in extent and duration to those usually achieved in man. The plasma concentrations of AT III and HC II did not vary under treatment. The half-life of the elimination phase in the placebo group ranged from 1.95 to 2.33 d for AT III and from 1.96 to 2.21 d for HC II. There was no significant difference in the half-lives of the 2 inhibitors between the placebo group and the animals receiving heparin or PPS. This suggests that clinical conditions associated with heparin treatment may be important for the effect of heparin on AT III metabolism previously reported in patients. When the data of the nine animals were pooled, a strong positive correlation (p <0.001) between the halflives of AT III and HC II was found, indicating similarities in the catabolic pathways of these two parent molecules.
Collapse
Affiliation(s)
- P Sié
- The Laboratoire d’Hémostase, CRTS, Hôpital Purpan, Toulouse, France
| | - J Lansen
- The Centre de Recherche Clin-Midy-Groupe Sanofi, Montpellier, France
| | - F Lacheretz
- The Centre de Recherche Clin-Midy-Groupe Sanofi, Montpellier, France
| | - B Verschuere
- The Centre de Recherche Clin-Midy-Groupe Sanofi, Montpellier, France
| | - B Boneu
- The Laboratoire d’Hémostase, CRTS, Hôpital Purpan, Toulouse, France
| |
Collapse
|
24
|
Boneu A, Sié P, Bugat R, Caranobe C, Eber M, Cazenave JP, Boneu B. Platelet Regeneration Time After Aspirin Ingestion and Platelet Survival Time After Labelling with 51Chromium or 111Indium Oxine – A Comparative Study. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661289] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA simultaneous investigation of platelet regeneration time (PRT) based upon malondialdehyde (MDA) recovery after a single oral intake of 500 mg of aspirin and of platelet survival time (PST) after labelling with 51chromium or 111Inindium oxine was performed in 25 cancerous patients. A pilot study conducted with 9 healthy volunteers demonstrated that the MDA assay was highly reproducible and specific for the platelet cycloxygenase activity. The pattern of MDA recovery after aspirin ingestion was linear in the healthy volunteers and in the patients presenting both a normal and an accelerated platelet turnover. PST were calculated using the four mathematical models recommended by the International Committee for Standardization in Hematology; the best fit was given by the multiple hit model in 22 cases and by the linear regression model in 3 cases. The mean results obtained in the patients investigated with the 51chromium were consistently shorter than those obtained in the patients investigated with the mindium oxine while the mean PRT were almost identical in the two groups. An excellent correlation between PRT and PST was observed after 111Indium oxine labelling and using the weighted mean method for PST determination. These results suggest that the 111Indium oxine technique is a better method for platelet labelling and that the results provided by the weighted mean method reflect more closely the in vivo platelet turnover than those provided by the multiple hit model.
Collapse
Affiliation(s)
- A Boneu
- The Service de Médecine Nucléaire, Centre Claudius Regaud, Toulouse, France
| | - P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - R Bugat
- The Service de Médecine Nucléaire, Centre Claudius Regaud, Toulouse, France
| | - C Caranobe
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - M Eber
- The Service de Médecine Nucléaire, Centre Paul Strauss, Strasbourg, France
| | - J P Cazenave
- The Service d’Hémostase et de Thrombose, Centre de Transfusion Sanguine, Strasbourg, France
| | - B Boneu
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
25
|
Sié P, Letrenne E, Caranobe C, Genestal M, Cathala B, Boneu B. Factor II Related Antigen and Antithrombin III Levels as Indicators of Liver Failure in Consumption Coagulopathy. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657171] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryIn order to detect impaired synthesis of blood coagulation factors associated to consumption coagulopathy, a simultaneous evaluation of factor II-related antigen (II rAg) and of antithrombin III (AT III) was carried out in 16 patients affected with severe defibrination. An in vitro preliminary study on plasma and serum demonstrated that the levels of II rAg and of AT III, assessed by the Laurell technique with Behring antisera, were not reduced by the coagulation process. The patients were, a posteriori, classified into two groups according to the absence (group A) or the presence (group B) of factors predisposing to liver failure such as metastasis, cirrhosis, and prolonged shock. II rAg and AT III levels are significantly correlated; they are in the normal range in group A but reduced in group B. Thus II rAg or AT III level determinations are useful markers in the detection of liver failure associated to the consumption phenomenon. These results also suggest that part of the decreased AT III levels reported in severe cases of disseminated intravascular coagulation may be the consequence of an associated liver failure.
Collapse
Affiliation(s)
- P Sié
- The Groupe d'Étude sur les Maladies du Sang, Laboratoire d'Hémostase, Centre Régional de Transfusion Sanguine, Toulouse, France
| | - E Letrenne
- The Groupe d'Étude sur les Maladies du Sang, Laboratoire d'Hémostase, Centre Régional de Transfusion Sanguine, Toulouse, France
| | - C Caranobe
- The Groupe d'Étude sur les Maladies du Sang, Laboratoire d'Hémostase, Centre Régional de Transfusion Sanguine, Toulouse, France
| | - M Genestal
- The Service de Réanimation Respiratoire, Hôpital Purpan, Toulouse, France
| | - B Cathala
- The Service de Réanimation Respiratoire, Hôpital Purpan, Toulouse, France
| | - B Boneu
- The Groupe d'Étude sur les Maladies du Sang, Laboratoire d'Hémostase, Centre Régional de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
26
|
Xuereb JM, Sié P, Boneu B, Constans J. Up-regulation of Tissue Factor Expression by Platelet-derived Growth Factor in Human Vascular Smooth Muscle Cells in Culture. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1665445] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryHuman vascular smooth muscle cells (SMCs) isolated from normal adult arteries were investigated for the expression of Tissue Factor (TF) procoagulant activity at their membrane surface and TF antigen in lysed cells. In growing conditions, SMCs expressed high levels of TF activity and antigen. When cells were made quiescent by 72 h of subculture in serum-poor medium, these levels fell to about one third of the initial values. Platelet-derived growth factor BB (PDGF) up-regulated in a dose-dependent manner TF expression with a significant increase (1.8 fold) within five hours. PD 98059, a specific inhibitor of mitogen-activated protein kinase (MAPK) pathway involved in cell response to PDGF, also prevented TF up-regulation. Short-term treatment by Pentoxifylline and dibutyryl cAMP also completely prevented induced TF up-regulation, but remained without effect on baseline levels of quiescent, unstimulated cells. At their effective concentrations, pentoxifylline and dibutyryl cAMP also inhibited the activation of MAPK induced by PDGF. The rapid induction of TF upon growth factor stimulation may be important in circumstances where SMCs proliferate, such as vascular events or vessel development.
Collapse
Affiliation(s)
- J M Xuereb
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - P Sié
- Faculté des Sciences Pharmaceutiques et Biologiques, UPS, Toulouse, France
| | - B Boneu
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - J Constans
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| |
Collapse
|
27
|
Affiliation(s)
- P Sié
- Laboratoire d’Hémostase, CHU-Purpan, Toulouse, France
| | - Y Cadroy
- Laboratoire d’Hémostase, CHU-Purpan, Toulouse, France
| | - A Elias
- Service d’Angiologie, CHU-Rangueil, Toulouse, France
| | - H Boccalon
- Service d’Angiologie, CHU-Rangueil, Toulouse, France
| | - B Boneu
- Laboratoire d’Hémostase, CHU-Purpan, Toulouse, France
| |
Collapse
|
28
|
Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649967] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis paper reports the results of the first administration of the synthetic natural pentasaccharide with high affinity to antithrombin III (NP) in man. The study was mainly focused upon the pharmacokinetic properties and general tolerance of the compound. Subcutaneous injections of doses <1.43 mg (1000 anti Xa IU) did not generate measurable anti-Xa activities. After subcutaneous injection of increasing doses from 1.43 to 22.9 mg (1000 to 16000 anti-Xa IU) to young healthy volunteers, it was found that the maximal concentration (Cmax) and the area under curve (AUC) were linearly correlated to the dose, that the total plasma clearances (Cl) were constant and almost 3 times lower than those of the current low molecular weight heparins. Cmax were reached between 1 h and 3 h after the injection and the half-lives (t1/2) were remarkably constant (13.1 h to 13.9 h). During the first 24 h following the injection, around 50% of the total administered dose was recovered in the urine in an active form, indicating that kidney plays a major role in the elimination of NP. Consistent with these results, when NP was administered to healthy elderly volunteers having a lower creatinine clearance, the half-life of the compound was longer and the clearance lower. At doses exceeding 22.9 mg, Cmax, and AUC were slightly lower than expected, the percentage of the dose recovered in the urine and the total apparent plasma clearance increased, suggesting that the excess of NP unbound to antithrombin III was excreted faster. NP was also administered at various dosages once or twice a day for 7 days to 20 elderly volunteers. Due to the long half-life of the compound the “steady state” was obtained 2 to 3 days after the first injection at which the mean Cmax was increased 1.5 to 2 times. The general tolerance of the compound was excellent. No relevant prolongations of the prothrombin time, of the activated partial thromboplastin time or of the bleeding time were observed. A re-bleeding phenomenon of the bleeding time incision, probably related to friability of the haemostatic plug, occurred in 3 subjects treated with the highest dose regimens: single injection of 26.6 mg (20000 anti-Xa IU) (young volunteers) and repeated injections of 11.4 mg (8000 anti-XaIU) once a day for 7 days (elderly volunteers). At these times, plasma NP concentrations were between 2.9 and 3.6 μg ⋅ ml-1 (2 and 2.5 anti-Xa IU ⋅ ml-1).
Collapse
Affiliation(s)
- B Boneu
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Toulouse, France
| | - J Necciari
- The Sanofi Recherche, Montpellier, France
| | - R Cariou
- The Sanofi Recherche, Montpellier, France
| | - P Sié
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Toulouse, France
| | - A M Gabaig
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Toulouse, France
| | - G Kieffer
- The Sanofi Recherche, Montpellier, France
| | | | - G Lamond
- The Organon International, Oss, The Netherlands
| | - H Moelker
- The Organon International, Oss, The Netherlands
| | - T Mant
- The Guy’s Drug Research Unit, London, United Kingdom
| | - H Magnani
- The Organon International, Oss, The Netherlands
| |
Collapse
|
29
|
Goudemand J, Caron C, De Prost D, Derlon A, Borg JY, Sampol J, Sié P. Evaluation of Sensitivity and Specificity of a Standardized Procedure Using Different Reagents for the Detection of Lupus Anticoagulants. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1655965] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study was designed to test the sensitivity and specificity of a combination of 3 phospholipid-dependent assays performed with various reagents, for the detection of lupus anticoagulant (LA). Plasmas containing an LA (n = 56) or displaying various confounding pathologies [58 intrinsic pathway factor deficiencies, 9 factor VIII inhibitors, 28 plasmas from patients treated with an oral anticoagulant (OAC)] were selected. In a first step, the efficiency of each assay and reagent was assessed using the Receiving Operating Characteristic (ROC) method. Optimal cut-offs providing both sensitivity and specificity ≥80% were determined. The APTT assay and most of the phospholipid neutralization assays failed to discriminate factor VIII inhibitors from LA. In a second step, using the optimal cut-offs determined above, the results of all the possible combinations of the 3 assays performed with 4 different reagents were analyzed. Thirteen combinations of reagents allowed ≥ 80% of plasmas of each category (LA, factor deficiency or OAC) to be correctly classified (3/3 positive test results in LA-containing plasmas and 0/3 positive results in LA-negative samples).
Collapse
Affiliation(s)
- J Goudemand
- Laboratoire d’Hématologie, Hôpital Huriez, Lille
| | - C Caron
- Laboratoire d’Hématologie, Hôpital Huriez, Lille
| | - D De Prost
- Service d’Hématologie, Hôpital Bichat, Paris
| | - A Derlon
- Laboratoire d’Hématologie, CHRU Côte de Nacre, Caen
| | - J Y Borg
- Laboratoire d’Hématologie, Hôpital Charles Nicolle, Rouen
| | - J Sampol
- Laboratoire d’Hématologie, Faculté de Pharmacie, Marseille
| | - P Sié
- Laboratoire d’Hématologie, Hôpital Purpan, Toulouse, France
| | | |
Collapse
|
30
|
Abstract
SummaryWe examined the ability of unfractionated heparin to modulate the procoagulant activities of stimulated endothelial cells (EC). Confluent human venous umbilical EC were incubated with heparin before or after stimulation, then rinsed extensively to eliminate any heparin in the solution. EC, stimulated for 4 h with endotoxin and interleukin 1β, expressed tissue factor and prothrombinase activities. When EC were treated with heparin (6 and 60 μg/ml) during the last 10 min of the stimulation period, EC-related procoagulant activities were inhibited in a dose-dependent manner (80-90% inhibition at 60 μg/ml). The inhibition was antithrombin-dependent and it disappeared after heparin removal in less than 15 min at 37° C but persisted at 4° C.When EC were treated with heparin (60 μg/ml) for 24 h then extensively washed before stimulation, the anticoagulant effect was more modest (50% inhibition). The effect was antithrombin-dependent. Inhibition was maximum after 18-24 h of pretreatment of EC with heparin and was stable for at least 7 h. The cell surface displayed a “heparin-like” activity: treatment by heparin doubled the rate of thrombin-antithrombin complex formation and this effect was heparinase sensitive and chondroitinase ABC insensitive.Thus, heparin modulates the procoagulant properties of stimulated EC according to two distinct mechanisms. The first one is rapid and transient, probably related to the presence of heparin molecules bound at the membrane surface. The second is delayed and persistent, and our results suggest that it is mediated by an increase in the membrane heparan sulfate molecules.
Collapse
Affiliation(s)
- Y Cadroy
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - D Gaspin
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - D Dupouy
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | | | - B Boneu
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - P Sié
- The Faculté de Sciences Pharmaceutiques, Toulouse, France
| |
Collapse
|
31
|
Cadroy Y, Sié P, Alhenc-Gelas M, Aiach M. Evaluation of APC Resistance in the Plasma of Patients with Q506 Mutation of Factor V (Factor V Leiden) and Treated by Oral Anticoagulants. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1653856] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Y Cadroy
- Laboratoire d’Hématologie, Hôpital Purpan, Toulouse, France
| | - P Sié
- Laboratoire d’Hématologie, Hôpital Purpan, Toulouse, France
| | - M Alhenc-Gelas
- Laboratoire d’Hémostase, Hôpital Broussais, Paris, France
| | - M Aiach
- Laboratoire d’Hémostase, Hôpital Broussais, Paris, France
| |
Collapse
|
32
|
Roussi J, Drouet L, Samama M, Sié P, Bal C, Boudaoud L, Cazenave JP, Denninger MH, Droule C, Horellou MH, Levy G, Mazoyer E, Sampol J, Schved JF, Vergnes C. French Multicentric Evaluation of Recombinant Tissue Factor (Recombiplastin) for Determination of Prothrombin Time. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1648945] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryRecombiplastin, a recombinant a human tissue factor, elaborated by Ortho Diagnostic Systems, produced by Baculovirus and relipidated with highly purified phospholipids, was tested as a new reagent for determining prothrombin time (PT) in a French multicentric study. Its intralaboratory- performances, including sensitivity, repeatability, reproducibility and stability, were explored to establish whether its use would reduce the interlaboratory dispersion of PT values, and therefore improve the standardization of oral anticoagulant treatment.The 9 university hospital hematology laboratories involved in this study used the same type of instrument (KC 10). For 10 consecutive days, they determined PTS on a normal plasma pool, plasma dilutions of 1/2, 1/3 and 1/8, 3 identical lyophilized calibrated plasmas, as well as plasmas from 20 normal subjects, 50 patients on oral anticoagulant therapy with Recombiplastin which has an International Sensitivity Index (ISI) of 1, and 2 commercial thromboplastin extracts (ISI #1 or 2). In the patients on anticoagulants, factors VII, X and V were measured when results were conflicting.The intra and interlaboratory reproducibilities of Recombiplastin, calculated on the basis of either PTS expressed in seconds, or of the International Normalized Ratio (INR), were good, with coefficients of variation (CV) similar to those observed with the 5 other reagents used by the different laboratories (2% <CV <8%).The stability of Recombiplastin was excellent, with no variation in PT after 72 h of incubation at 37° C.A normal PT of 12 s was obtained with Recombiplastin, similar to the values found for the reagents with ISI #2. In the patients on anticoagulants, Recombiplastin gave the longest coagulation times (PTRecombipiastin = 64.2 s vs PTNeoPlastin = 32.8 s, and PTThromborel = 54.4 s). These results suggest that Recombiplastin is highly sensitive to the changes in coagulation induced by anticoagulants. Recombiplastin was more sensitive to factor VII deficiency than any of the other reagents, even those with ISI #1.The coefficients of correlation between the INRS calculated on the basis of the PTS obtained with Recombiplastin and the INRS based on the PTS for other thromboplastins, were satisfactory (0.85 <R <0.95) but a breakpoint in the slope of the regression curves was observed when INR >4. This observation requires further investigation, particularly in connection with the exact ISI values for Recombiplastin and the other thromboplastins used in this study.In conclusion, Recombiplastin is stable and sensitive and gives accurate reproducible results. However, the behavior of Recombiplastin is slightly different from that of the commercial reagents whether their ISI is 1 or 2, and its use did not reduce the interlaboratory dispersion of PT values.
Collapse
Affiliation(s)
- J Roussi
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - L Drouet
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - M Samama
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - P Sié
- The Hospital Hematology Laboratories in Toulouse, France
| | - C Bal
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - L Boudaoud
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - J P Cazenave
- The Hospital Hematology Laboratories in Strasburg, France
| | - M H Denninger
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - Ch Droule
- The Hospital Hematology Laboratories in Reims, France
| | - M H Horellou
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - G Levy
- The Hospital Hematology Laboratories in Marseilles, France
| | - E Mazoyer
- The Hospital Hematology Laboratories in Paris (R. Poincaré, Lariboisière, Hôtel Dieu and Beaujon Hospitals)
| | - J Sampol
- The Hospital Hematology Laboratories in Marseilles, France
| | - J F Schved
- The Hospital Hematology Laboratories in Nîmes, France
| | - C Vergnes
- The Hospital Hematology Laboratories in Bordeaux, France
| |
Collapse
|
33
|
Diquélou A, Dupouy D, Gaspin D, Constans J, Sié P, Boneu B, Sakariassen KS, Cadroy Y. Relationship between Endothelial Tissue Factor and Thrombogenesis under Blood Flow Conditions. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649812] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have evaluated the relationship between the level of tissue factor (TF) expression by stimulated endothelial cells and thrombus formation under blood flow conditions. Cultures of human umbilical venous endothelial cells (HUVECs) were treated in order to express different levels of TF activity. They were stimulated for 4 h with either I) lipopolysaccharides (LPS, 10 µg/ml), II) recombinant interleukin Iß (IL1ß, 50 Ul/ml) or III) simultaneously with LPS and IL1ß (LPS + IL1ß). TF activity was low on confluent HUVECs or on the corresponding extracellular-matrix (ECM prepared by exposure of HUVECs to 0.1 N NH4OH). In contrast, it was high when HUVECs were stimulated with LPS or IL1ß, and significantly higher (p <0.05) with LPS+IL1ß. The TF activity associated with the stimulated ECM was 2-fold higher (p <0.05) than that expressed on the luminal surface of the stimulated HUVECs, irrespective of the agonist or combination of agonists used.These surfaces were exposed to non-anticoagulated human blood at a venous (50 s-1) and an arterial (650 s-1) wall shear rate in parallel-plate perfusion chambers for 5 min. Thrombus formation was morphologically quantified by measuring the deposition of platelets and fibrin. Fibrin deposition was also immunologically quantified. Fibrin deposition was related to the level of TF expression. Non-stimulated HUVECs and corresponding ECMs were not thrombogenic. The luminal surface of HUVECs stimulated with LPS or IL1ß alone expressed low levels of TF activity and was a poor inducer of platelet deposition and fibrin deposition (<15%) at 50 s-1. In contrast, fibrin deposition increased to 80% when the cells were stimulated with LPS and IL1ß simultaneously. This fibrin deposition was comparable to that found on the corresponding ECM, despite a two-fold lower TF activity. However, at 650 s-1, platelet and fibrin deposition on HUVECs stimulated with LPS + IL1ß were significantly lower than that observed on the corresponding ECM. In all circumstances, the thrombogenicity was TF-dependent, since fibrin deposition was totally blocked by anti-TF antibodies. Thus, it appears that the level of TF activity expressed on endothelial cells governs thrombus formation. However, the impact of TF expression on thrombus formation is also affected by the blood flow.
Collapse
Affiliation(s)
- Armelle Diquélou
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - Dominique Dupouy
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - Dominique Gaspin
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - Jacques Constans
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - Pierre Sié
- The Faculté de Sciences Pharmaceutiques, Toulouse, France
| | - Bernard Boneu
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| | - Kjell S Sakariassen
- The Nycomed Bioreg AS, Haemostasis and Thrombosis Research Unit, Oslo, Norway
| | - Yves Cadroy
- The Laboratoire de Recherche sur I’Hémostase et la Thrombose, Hôpital Purpan, Toulouse, France
| |
Collapse
|
34
|
Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sié P, Boccalon H, Boneu B. Influence of Long Term Oral Anticoagulants upon Prothrombin Fragment 1 + 2, Thrombin-Antithrombin III Complex and D-Dimer Levels in Patients Affected by Proximal Deep Vein Thrombosis. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1651601] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have investigated the influence of long term oral anticoagulants (OAC) upon the plasma levels of prothrombin fragment 1 + 2 (F1 + 2), of thrombin-antithrombin III complexes (TAT) and of D-Dimer in 20 patients affected by a proximal deep vein thrombosis (DVT) diagnosed by ultrasonic duplex scanning. Patients (63 ± 17 years, mean ± SD) were sampled at the beginning of the OAC treatment (day 1), which was started 1 to 6 days after diagnosis confirmation and full heparinization, and then 8, 35 and 92 days after. The results were compared to those obtained in a blood donor population (39 ± 10 years) and to an age-matched healthy population (63 ± 19 years). The mean INR determined on days 8, 35 and 92 were almost identical (2.8 ± 0.7, 2.9 ± 0.9 and 2.8 ± 0.6 respectively). In contrast, highly significant variations of the three markers were recorded during the observation period. Eight days after the beginning of OAC, increased levels of TAT complexes were associated with subnormal levels of F1 + 2 suggesting persistence of a hypercoagulable state. On the further sampling times, TAT complexes were in the normal range while F1 + 2 were far below the normal range. Between day 1 and day 92, the levels of D-Dimer continuously decreased reflecting a long-term fibrinolytic process.This study clearly indicates that high INR are not systematically associated with very low F1 + 2 levels, particularly in the acute phase of thrombosis. Whether or not it is possible to reduce the intensity of the anticoagulant treatment 1 month after its initiation on the basis of very low levels of F1 + 2 can only be determined by prospective clinical trials.
Collapse
Affiliation(s)
- A Elias
- Service d′Angiologie, Hôpital de Rangueil, Toulouse, France
| | - S Bonfils
- Laboratoire d'Hémostase, Centre de Transfusion, Toulouse, France
| | - M Daoud-Elias
- Service d′Angiologie, Hôpital de Rangueil, Toulouse, France
| | - B Gauthier
- Service d′Angiologie, Hôpital de Rangueil, Toulouse, France
| | - P Sié
- Laboratoire d'Hémostase, Centre de Transfusion, Toulouse, France
| | - H Boccalon
- Service d′Angiologie, Hôpital de Rangueil, Toulouse, France
| | - B Boneu
- Laboratoire d'Hémostase, Centre de Transfusion, Toulouse, France
| |
Collapse
|
35
|
Saivin S, Petitou M, Lormeau JC, Dupouy D, Sié P, Caranobe C, Houin G, Boneu B. Pharmacological Properties of a Low Molecular Weight Butyryl Heparin Derivative (C4-CY 216) with Long Lasting Effects. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1648445] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have investigated the pharmacological properties of an O-acylated butyryl derivative of the low molecular weight heparin CY 216 (C4-CY 216). In a purified system the ability of C4-CY 216 to catalyze thrombin and factor Xa inhibition was comparable to that of CY 216. The antithrombin and antifactor Xa catalytic efficiencies of C4-CY 216 were reduced 217 and 12 times respectively when albumin (10 mg ml-1) was added to the reagents, while those of CY 216 were essentially unchanged. In plasma, the antifactor Xa specific activity of C4-CY 216 was close to that of CY 216 but the antithrombin specific activity was 2 times lower. After bolus and continuous intravenous injection to rabbits, the clearances of the two activities of C4-CY 216 were on average half the corresponding values of CY 216. After subcutaneous injection, the bioavailability of C4-CY 216 was comparable to that of CY 216. C4-CY 216 was as potent as CY 216 in preventing venous thrombosis in the thromboplastin-Wessler model and the duration of the antithrombotic effect was longer than that of the parent compound. The chemical alteration of CY 216 did not enhance the prohaemorrhagic effect in the rat tail transection model. Therefore, the new concept of heparin derivative having a low clearance and long lasting effects that we have recently reported for unfractionated heparin may also be applied to a low molecular weight heparin.
Collapse
Affiliation(s)
- S Saivin
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse
- Unité de pharmacocinétique clinique, Hôpital Purpan, Toulouse
| | - M Petitou
- Institut Sanofi-Choay, Gentilly, France
| | | | - D Dupouy
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse
| | - P Sié
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse
| | - C Caranobe
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse
| | - G Houin
- Unité de pharmacocinétique clinique, Hôpital Purpan, Toulouse
| | - B Boneu
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse
| |
Collapse
|
36
|
Boneu B, Bes G, Pelzer H, Sié P, Boccalon H. D-Dimers, Thrombin Antithrombin III Complexes and Prothrombin Fragments 1 + 2: Diagnostic value in Clinically Suspected Deep Vein Thrombosis. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647449] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis study was performed to determine the accuracy of D-Dimer fibrin derivatives, thrombin-antithrombin III (TAT) complexes and prothrombin fragments 1 + 2 (F 1 + 2) determinations for the diagnosis of deep vein thrombosis (DVT). One hundred and sixteen consecutive patients referred to the angiology unit of our hospital for a clinically suspected DVT were investigated. They were submitted to mercury strain gauge plethysmography and to ultrasonic duplex scanning examination; in cases of inconclusive results or of proximal DVT (n = 35), an ascending phlebography was performed. After these investigations were completed, the diagnosis of DVT was confirmed in 34 and excluded in 82. One half of the patients were already under anticoagulant therapy at the time of investigation. The 3 biological markers were assayed using commercially available ELISA techniques and the D-Dimer was also assayed with a fast latex method. The normal distribution of these markers was established in 40 healthy blood donors. The most accurate assay for the diagnosis of DVT was the D-Dimer ELISA which had both a high sensitivity (94%) and a high negative predictive value (95%). The D-Dirner latex, TAT complexes and F 1 + 2 were far less sensitive and provided negative predictive values which ranged between 78 and 85%. In spite of positive and significant correlations between the levels of ihe 3 markers, their association did not improve their overall accuracy for detecting D\/L Therefore, with the exception of the D-Dimer ELISA, these markers were of little value for the diagnosis of DVT in this specific population.
Collapse
Affiliation(s)
- B Boneu
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - G Bes
- Unité d’Angiologie, Hôpital de Rangueil, Toulouse, France
| | - H Pelzer
- Department of Blood Coagulation, Behringwerke AG, Marburg, Germany
| | - P Sié
- Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - H Boccalon
- Unité d’Angiologie, Hôpital de Rangueil, Toulouse, France
| |
Collapse
|
37
|
Preissner KT, Sié P. Modulation of Heparin Cofactor II Function by S Protein (Vitronectin) and Formation of a Ternary S Protein-Thrombin-Heparin Cofactor II Complex. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646979] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe complement inhibitor S protein, which is identical to the adhesive protein vitronectin, functions as heparin-neutralizing factor by protecting thrombin as well as factor Xa against fast inactivation by antithrombin III. The interference of S protein with glycosaminoglycan-catalyzed inhibition of thrombin by heparin cofactor II was investigated in these studies. S protein significantly counteracted the anticoagulant activity of heparin and pentosan polysulfate but not of dermatan sulfate. In the presence of 0.3 μg/ml heparin, 0.5 μg/ml pentosan polysulfate, or 2 μg/ml dermatan sulfate, S protein induced a concentrationdependent
reduction of the inhibition rate of thrombin by heparin cofactor II. This resulted in a decrease of the apparent pseudo first-order rate constants by about 17-fold (heparin), or about 7-fold (pentosan polysulfate), whereas no neutralization of dermatan
sulfate was demonstrable at a physiological ratio of S protein to heparin cofactor II. Exposure of the glycosaminoglycan-binding region of S protein by reduction and carboxymethylation of the protein increased the neutralizing activity of S protein towards heparin and pentosan polysulfate. The results of these functional experiments correlated well with the demonstration of direct binding of S protein to both polysaccharides but not to
dermatan sulfate. While reduced/carboxymethylated S protein remained also ineffective in neutralizing other dermatan sulfate compounds with varying degree of sulfation, a synthetic highly basic tridecapeptide, representing a portion of the glycosaminoglycan-binding domain of S protein, counteracted their anticoagulant activity. Independent on the polysaccharide used, S protein was found incorporated within a ternary complex with thrombin and heparin cofactor II during the inhibition reaction as judged by crossed immunoelectrophoresis, ultracentrifugation as well as ELISA analysis, emphazising the function of S protein as scavenger protein for enzyme-inhibitor complexes of the coagulation system. These findings demonstrate the role of S protein as effective neutralising plasma protein of the anticoagulant activity of various glycosaminoglycans also with respect to heparin cofactor II. Although the glycosaminoglycan-binding domain of S protein readily neutralized different dermatan sulfate compounds, physiological modulation of heparin cofactor-II-dependent
inhibition of thrombin by native S protein appears to be restricted to the vascular compartments, where other glycosaminoglycans than dermatan sulfate appear to be operative.
Collapse
Affiliation(s)
| | - Pierre Sié
- The Clinical Research Unit for Blood Coagulation and Thrombosis of the Max-Planck-Gesellschaft, Justus-Liebig-Universität Gießen, FRG and the Hemostasis Laboratory
| |
Collapse
|
38
|
Piétu G, Thomas-Maison N, Sié P, Larrieu MJ, Meyer D. Haemophilia A in a Female: Study of a Family Using Intragenic and Extragenic Restriction Site Polymorphisms. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647644] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryRestriction fragment length polymorphisms(RFLPs) were studied in a large Algerian family which includes 6 haemophiliacs and a previously described case of female haemophilia A. The female propositus is 66 years old with a normal karyotype. Her parents are first cousins. Her 3 sons are haemophiliacs and her 3 daughters with affected children are obligate carriers. The proband has an excessive bleeding tendency and markedly reduced levels of F. VIII (VIII C 0.03 U/ml, VIII Ag 0.01 U/ml) with elevated vWF Ag (2.30 U/ml), similar to the levels observed in affected males from the family. Four RFLPs can be identified by Southern blotting after digesting genomic DNA with the restriction enzymes Bcl I, Bgl I, Kpn I/Xba I and Taq I and hybridization with a 647 bp Stu I/Sca I F. VIII genomic probe, a 1.8 Kb EcoRI F. VIII cDNA probe, a 1.0 Kb EcoRI/Sst I fragment of intron 22 and the extragenic probe ST 14, respectively. With these four RFLPS, the propositus was found to be homozygous for the alleles segregating in this family with the abnormal X-chromosome. The carrier status was proven in a granddaughter and excluded in another. In conclusion, this RFLP linkage analysis is another argument to suggest that the propositus, a rare case of female haemophilia, is homozygous for the abnormal gene.
Collapse
Affiliation(s)
- G Piétu
- The INSERM U.143, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - N Thomas-Maison
- The INSERM U.143, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - P Sié
- The Laboratoire d’Hémostase, Centre de Transfusion Sanguine, Toulouse, France
| | - M J Larrieu
- The INSERM U.143, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - D Meyer
- The INSERM U.143, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
39
|
Affiliation(s)
- P Sié
- Laboratoires d'Hématologie, CHU Purpan et Rangueil, 31052 Toulouse cedex, France
| | - B Boneu
- Laboratoires d'Hématologie, CHU Purpan et Rangueil, 31052 Toulouse cedex, France
| | - R Biermé
- Laboratoires d'Hématologie, CHU Purpan et Rangueil, 31052 Toulouse cedex, France
| | - M L Wiesel
- Service d'Hémostase et de Thrombose, INSERM U 311, Centre de Transfusion Sanguine, 67085 Strasbourg cedex, France
| | - L Grunebaum
- Service d'Hémostase et de Thrombose, INSERM U 311, Centre de Transfusion Sanguine, 67085 Strasbourg cedex, France
| | - J P Cazenave
- Service d'Hémostase et de Thrombose, INSERM U 311, Centre de Transfusion Sanguine, 67085 Strasbourg cedex, France
| |
Collapse
|
40
|
Ofosu FA, Fernandez F, Anvari N, Caranobe C, Dol F, Cadroy Y, Petitou M, Mardiguian J, Sié P, Boneu B. Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647027] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA recent study (Fernandez et al., Thromb. Haemostas. 1987; 57: 286-93) demonstrated that when rabbits were injected with the minimum weight of a variety of glycosaminoglycans required to inhibit tissue factor-induced thrombus formation by —80%, exogenous thrombin was inactivated —twice as fast in the post-treatment plasmas as the pre-treatment plasmas. In this study, we investigated the relationship between inhibition of thrombus formation and the extent of thrombin inhibition ex vivo. We also investigated the relationship between inhibition of thrombus formation and inhibition of prothrombin activation ex vivo. Four sulfated polysaccharides (SPS) which influence coagulation in a variety of ways were used in this study. Unfractionated heparin and the fraction of heparin with high affinity to antithrombin III potentiate the antiproteinase activity of antithrombin III. Pentosan polysulfate potentiates the activity of heparin cofactor II. At less than 10 pg/ml of plasma, all three SPS also inhibit intrinsic prothrombin activation. The fourth agent, dermatan sulfate, potentiates the activity of heparin cofactor II but fails to inhibit intrinsic prothrombin activation even at concentrations which exceed 60 pg/ml of plasma. Inhibition of thrombus formation by each sulfated polysaccharides was linearly related to the extent of thrombin inhibition achieved ex vivo. These observations confirm the utility of catalysis of thrombin inhibition as an index for assessing antithrombotic potential of glycosaminoglycans and other sulfated polysaccharides in rabbits. With the exception of pentosan polysulfate, there was no clear relationship between inhibition of thrombus formation and inhibition of prothrombin activation ex vivo.
Collapse
Affiliation(s)
- F A Ofosu
- The McMaster University, Gennevilliers, France
| | - F Fernandez
- The McMaster University, Gennevilliers, France
| | - N Anvari
- The McMaster University, Gennevilliers, France
| | - C Caranobe
- Canadian Red Cross Society, BTS, Hamilton, Ont. Canada, the Laboratoire d’Hemostase, Gennevilliers, France
| | - F Dol
- Canadian Red Cross Society, BTS, Hamilton, Ont. Canada, the Laboratoire d’Hemostase, Gennevilliers, France
| | - Y Cadroy
- Canadian Red Cross Society, BTS, Hamilton, Ont. Canada, the Laboratoire d’Hemostase, Gennevilliers, France
| | - M Petitou
- Centre de Transfusion Sanguine, Toulouse, France, the Institut Choay, Paris, France
| | - J Mardiguian
- The Laboratoires Pharmuka, Gennevilliers, France
| | - P Sié
- Canadian Red Cross Society, BTS, Hamilton, Ont. Canada, the Laboratoire d’Hemostase, Gennevilliers, France
| | - B Boneu
- Canadian Red Cross Society, BTS, Hamilton, Ont. Canada, the Laboratoire d’Hemostase, Gennevilliers, France
| |
Collapse
|
41
|
Abstract
SummaryA simple method for biological assay of dermatan sulfate (DS) in plasma is described. DS accelerates thrombin inhibition by heparin cofactor II (HC II). The principle of the assay is to measure the residual amidolytic thrombin activity after a short period of incubation with HC II in defibrinated plasma at low ionic strength. For this method we take advantage of two observations. Firstly, at fixed concentrations of DS and of HC II, the rate of thrombin inhibition increases when the ionic strength of the medium decreases. Secondly, defibrination by bentonite absorption also removes antithrombin III, HC II and for a large part alpha-2 macroglobulin from the plasma, so that no other thrombin inhibitor competes with HC II added as a reagent in a second step.In the conditions described, there is a linear relationship between DS concentrations in plasma from 0 to 2 μg/ml and the log of residual thrombin activity. The limit of sensitivity is 0.1 μg/ ml. The assay displays an acceptable reproducibility in intraassay, inter-assay and inter-individual experiments. It can be used to measure DS in human, rabbit and rat plasmas. The assay is also sensitive to other HC II activators such as heparin and pentosan polysulfate.DS is effective in experimental thrombosis without any detectable anticoagulant effect ex vivo. Pharmacological concentrations of DS in plasma fall into the range of sensitivity of this assay, which would be helpful in experimental or clinical studies of DS and related glycosaminoglycans.
Collapse
Affiliation(s)
- D Dupouy
- The Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Hôpital Purpan, Toulouse, France
| | - P Sié
- The Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Hôpital Purpan, Toulouse, France
| | - F Dol
- The Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Hôpital Purpan, Toulouse, France
| | - B Boneu
- The Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Hôpital Purpan, Toulouse, France
| |
Collapse
|
42
|
Sié P, Aillaud MF, Prost DD, Droullé C, Forestier F, Guedj P, Juhan-Vague I, Polack B, Potron G, Roncato M, Roussi J, Sampol J, Aiach M. Measurement of Low Molecular Weight Heparin Ex Vivo Activities in Clinical Laboratories Using Various Anti-Xa Assays: Interlaboratory Variability and Requirement for an Agreed Low Molecular Weight Heparin Standard. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe only sensitive and convenient assay to assess the biological activity of low molecular weight heparins (LMWHs) is based on the potentiation of activated factor Xa inhibition. Several procedures for measuring the socalled anti Xa activity have been proposed. In this collaborative study including eight laboratories, we have used four different assays (three amidolytic and one clotting based methods) for measuring the anti Xa activity of ex vivo samples obtained after injecting three different LMWHs. The dispersion of the results obtained by calibration against standard heparin could be reduced by using any of the three LMWHs for calibration. A coefficient of variation less than 0.20 between values obtained in different laboratories using a variety of methods seems acceptable. However it is necessary to refer to a common international standard for expressing the results in units and to define, for each of the three products, the therapeutic range.
Collapse
Affiliation(s)
- P Sié
- The Haemostasis laboratories, Hôpital Purpan, Toulouse, France
- who coordinated the study
| | - M F Aillaud
- The CHU La Timone, Marseille, Boulogne, France
| | - D de Prost
- The CHU Xavier-Bichat, Paris, Boulogne, France
| | - C Droullé
- The CHU Robert-Debré, Reims, Boulogne, France
| | - F Forestier
- The Hôpital Notre-Dame de Bon-Secours, Paris, Boulogne, France
| | - P Guedj
- The Hôpital de la Conception, Marseille, Boulogne, France
| | | | - B Polack
- The CHRU, Grenoble, Boulogne, France
| | - G Potron
- The CHU Robert-Debré, Reims, Boulogne, France
| | - M Roncato
- The Hôpital Broussais, Paris, Boulogne, France
| | - J Roussi
- The Hôpital Ambroise-Paré, Boulogne, France
| | - J Sampol
- The Hôpital de la Conception, Marseille, Boulogne, France
| | - M Aiach
- The Hôpital Broussais, Paris, Boulogne, France
- who coordinated the study
| |
Collapse
|
43
|
Cadroy Y, Dol F, Caranobe C, Petitou M, Lormeau JC, Sié P, Choay J, Boneu B. Standard Heparin Enhances the Antithrombotic Activity of Dermatan Sulfate in the Rabbit but CY 216 Does Not. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1642774] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
SummaryStandard heparin (SH) and dermatan sulfate (DS) two gly- cosaminoglycans with different pharmacological targets are effective antithrombotic agents in the rabbit. We have investigated the antithrombotic activity of the association DS plus SH. It was found that doses as low as 25 µg/kg for DS and 10 µg/kg for SH were ineffective when injected separately but generated a high and significant antithrombotic activity when injected together. These results were confirmed when higher doses of each compound were delivered in association. Further experiments were performed to determine if the enhancement of the antithrombotic activity of DS by HS resulted from its anti-factor Ha or antifactor Xa activity or from its moiety without affinity to AT III. A low molecular weight heparin (CY 216) with an anti-factor Xa/ anti-factor Ha ratio of 5, the synthetic pentasaccharide bearing the minimum binding sequence to antithrombin III, and a low affinity fraction of SH to AT III did not increase the antithrombotic activity of DS; in contrast a high affinity fraction of SH to AT III had the same effect than SH. We conclude that the enhancement of the antithrombotic activity of DS by SH mainly results from its anti-factor IIa activity.
Collapse
Affiliation(s)
- Y Cadroy
- Laboratoire d’Hemostase, Centre de Transfusion Sanguine, Toulouse, France
| | - F Dol
- Laboratoire d’Hemostase, Centre de Transfusion Sanguine, Toulouse, France
| | - C Caranobe
- Laboratoire d’Hemostase, Centre de Transfusion Sanguine, Toulouse, France
| | | | | | - P Sié
- Laboratoire d’Hemostase, Centre de Transfusion Sanguine, Toulouse, France
| | - J Choay
- Institut Choay, Paris, France
| | - B Boneu
- Laboratoire d’Hemostase, Centre de Transfusion Sanguine, Toulouse, France
| |
Collapse
|
44
|
Marlu R, Jouve T, Polack B, Sié P, Mémier V. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations: comment. J Thromb Haemost 2018; 16:1017-1019. [PMID: 29460346 DOI: 10.1111/jth.13981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Indexed: 11/29/2022]
Affiliation(s)
- R Marlu
- Hemostasis Laboratory, Grenoble Alpes University Hospital, Grenoble, France
- Grenoble Alpes University, Grenoble, France
| | - T Jouve
- Grenoble Alpes University, Grenoble, France
- Nephrology Unit, Grenoble Alpes University Hospital, Grenoble, France
| | - B Polack
- Hemostasis Laboratory, Grenoble Alpes University Hospital, Grenoble, France
- Grenoble Alpes University, Grenoble, France
| | - P Sié
- Hemostasis Laboratory, Toulouse University Hospital, Toulouse, France
| | - V Mémier
- Hemostasis Laboratory, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
45
|
Négrier C, Ducloy-Bouthors AS, Piriou V, De Maistre E, Stieltjes N, Borel-Derlon A, Colson P, Picard J, Lambert T, Claeyssens S, Boileau S, Bertrand A, André MH, Fourrier F, Ozier Y, Sié P, Gruel Y, Tellier Z. Postauthorization safety study of Clottafact®
, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study. Vox Sang 2017; 113:120-127. [DOI: 10.1111/vox.12624] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 09/26/2017] [Accepted: 11/14/2017] [Indexed: 01/02/2023]
Affiliation(s)
| | | | - V. Piriou
- South University Hospital; Lyon France
| | | | | | | | - P. Colson
- University Hospital; Montpellier France
| | - J. Picard
- University Hospital; Grenoble France
| | - T. Lambert
- Bicêtre Hospital; Kremlin Bicêtre France
| | | | | | - A. Bertrand
- Medical Affairs; LFB Biomédicaments; Les Ulis France
| | - M.-H. André
- Medical Affairs; LFB Biomédicaments; Les Ulis France
| | | | - Y. Ozier
- University Hospital; Brest France
| | - P. Sié
- Rangueil Hospital; Toulouse France
| | - Y. Gruel
- Trousseau Hospital; Tours France
| | - Z. Tellier
- Medical Affairs; LFB Biomédicaments; Les Ulis France
| |
Collapse
|
46
|
Sakariassen K, Grandjean H, Thalamas C, Boneu B, Sié P, Cadroy Y. The Effect of Platelet PlA Polymorphism on Experimental Thrombus Formation in Man Depends on Blood Flow and Thrombogenic Substrate. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615972] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryA number of studies have reported conflicting data on the association of the PlA1/PlA2 polymorphism of the GPIIIa gene and coronary syndromes. We have investigated the effect of this polymorphism on experimental platelet thrombus formation in man. Forty healthy male volunteers were genotyped for the PlA1/PlA2 polymorphism. Thrombus formation was induced ex vivo by exposing a tissue factor (TF) or a collagencoated coverslip in a parallel plate perfusion chamber to native blood for 2 and 4 min. The shear rates at these surfaces were 650 and 2,600 s–1. Platelet and fibrin deposition was quantified by immunoenzymatic methods. The frequencies of PlA1/PlA1 and PlA1/PlA2 genotypes were 52.5% and 47.5%, respectively. Ex vivo deposition of fibrin on TF was not affected by the PlA1/PlA2 polymorphism. However, the ex vivo platelet deposition at 650 s–1 was higher in blood from PlA1/PlA1 individuals than in PlA1/PlA2 individuals (P = 0.008 at 4 min). On collagen, neither fibrin nor platelet deposition was significantly affected by the PlA1/PlA2 polymorphism. Platelet thrombus formation is significantly influenced by genetic variations in the GPIIIa platelet receptor. This effect depends on the blood flow properties and the nature of the thrombogenic stimulus.
Collapse
|
47
|
Querrec AL, Arnout J, Arnoux D, Borg JY, Caron C, Darnige L, Delahousse B, Reber G, Sié P. Quantification of Lupus Anticoagulants in Clinical Samples Using Anti- β2GP1 and Anti-Prothrombin Monoclonal Antibodies. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1616090] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryQuantification of lupus anticoagulant (LA) in clinical samples is hampered by the lack of a suitable standard of activity. We evaluated the use of mAbs displaying LA activity for this purpose. As most patient samples contain both β2Glycoprotein I (β2GP1) and prothrombin dependent LA, a combination of two mAbs, one of each specificity, was added to normal plasma in a concentration from 0 to 60 g/ml. Eight assay systems using different reagents and instruments were used. The calibration curves were linear for all but one, with marked differences between the responsiveness to each mAb. A panel of plasmas from 69 patients with persistent LA diagnosed using the SSCISTH criteria was tested. An antiphospholipid syndrome (APS) was present in 40, whereas 29 were asymptomatic. LA activities of individual plasmas varied between assays (p <10–4), but homogeneous subgroups were identified. In a majority of samples, LA activity displayed a prothrombin-dependent profile, with a variable contribution of β2GP1-dependent activity. The latter was associated to β2GP1 antibodies detected by solid-phase immunoassay. By using 3 dilute Russell viper venom time assays, higher LA titers were found in APS, compared to asymptomatic patients (p <0.05).
Collapse
|
48
|
Xuereb JM, Sié P, Boneu B, Constans J. Inhibition of Tissue Factor Synthesis by Disruption of ERK Kinases and PKC Signaling Pathways in Human Vascular SMCs. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1613980] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryTissue Factor (TF), the receptor for plasma VII/VIIa and the initiator of blood coagulation, is inducible in vascular smooth muscle cells (SMCs) by growth factors and bacterial lysopolysaccharides (LPS) and is expressed in vivo after vascular injury. As TF expression is a determinant of the thrombogenicity of vascular lesions, we investigated the signal pathways involved in this process.Human vascular SMCs were obtained from normal arteries and made quiescent by serum deprivation. Baseline TF antigen and activity were up-regulated by various agonists: fetal calf serum (FCS), LPS, and platelet derived growth factor (PDGF) being the most effectives but with different kinetics. TF expression induced by LPS was transient with a maximum 6 h after stimulation and returned to baseline levels after 24 h whereas TF expression induced by serum or PDGF was sustained for at least 24 h. Rapid and transient activation of Extracellular signal-Regulated Kinase (ERK) was observed after stimulation by PDGF and FCS, but not by LPS. The role of ERK, Ras and protein kinase C activities were investigated using specific inhibitors, PD 98059, manumycin A and calphostin C respectively. For TF induction by LPS, PKC activity was required and the ERK/Ras pathway was not involved. In contrast, the effect of PDGF was strictly ERK and Ras dependent, but partially prevented by PKC inhibitors. TF induction by FCS was ERK dependent but partially Ras and PKC dependent. In conclusion, TF expression appears to be a non-specific response of SMCs to numerous stimuli through multiple signal pathways which differ according to the inducing agent.
Collapse
|
49
|
Theveniau J, Coup D, Grégoire T, Vaillot M, Dupouy D, Sié P, Boneu B, Millet J, Masson P. Further Studies on the Mechanism for the Antithrombotic Effects of Naroparcil, an Orally Active Thioxyloside Compound. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614604] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe antithrombotic β-D-xyloside, naroparcil, has previously been shown to induce a dose-related increase of circulating glycosaminoglycans (GAGs) together with an antithrombin activity (anti-IIa) via heparin cofactor II (HCII) in the rabbit. In order to go further in the mechanisms, the relationship between the antithrombotic activity, the HCII-mediated anti-IIa activity and the plasma GAG content was investigated. We showed that the in vitro specific activity on the inhibition of thrombin by HCII of the plasma GAG extract from naroparcil-treated rabbits was increased by a factor of 60 when compared to controls. In addition, the fractionation of the plasma GAG extract by affinity chromatography on immobilized HCII led to a more potent material whereas the low-affinity fraction was shown to be inactive in thrombin inhibition by HCII.The qualitative analysis of GAGs showed the presence of the ΔDi-4S DS disaccharide, undetectable in control, which accounted for 22% in the unfractionated GAG extract and for 60% in the high affinity fraction. In vitro experiments using immuno-depleted plasma in antithrombin III (ATIII), HCII or both, indicated that the anti-IIa activity of the plasma GAG extract from naroparcil-treated rabbits was mainly due to HCII potentialisation. The unfractionated GAG extract and the high affinity fraction were shown to be antithrombotic in a Wessler-based model in the rat, giving ED80 values of 610 UA/kg and 56 UA/kg respectively whereas the low-affinity fraction was devoid of any antithrombotic activity. These results show that the antithrombotic activity of naroparcil is dependent on modification in the plasma GAG profile which inactivates thrombin via the HCII.
Collapse
|
50
|
Querrec L, Delahousse B, Caron C, Houbouyan L, Boutière B, Horellou M, Reber G, Sié P, Robert A. Control of Oral Anticoagulation in Patients with the Antiphospholipid Syndrome – Influence of the Lupus Anticoagulant on International Normalized Ratio. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615146] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe recommended therapeutic range of International Normalized Ratio (INR) for oral anticoagulant treatment in patients with the antiphospholipid syndrome remains controversial. As a part of this controversy, it has been suggested that lupus anticoagulants (LA) could interfere with the determination of prothrombin time, thus questioning the validity of monitoring the treatment of these patients using INR. To clarify this point, we compared the values of INR obtained in the plasmas of two groups of patients, one without LA (n = 47), and the other with LA (n = 43). INR were determined using 8 different thromboplastin reagents on the same automated coagulation instrument. Chromogenic factor X, which is supposed to be insensitive to the presence of LA, was also measured. The results are the following: provided INR was calculated using calibrated reference plasmas, there was no significant difference between INR values obtained with the 8 reagents, both in the non-LA and in the LA groups (CV: 5.9 and 6.7%, respectively). Closer examination revealed that INR results obtained with one reagent (the recombinant thromboplastin Innovin) diverged from those of the 7 others, leading to an overestimation of INR, to a very large extent in some instances. However this effect was restricted to a subset of the patient population with LA (6 out of 43). Finally, the relationship between INR (average value obtained using the 8 reagents) and factor X was identical in non-LA and in LA patient groups. We conclude that, provided the reagents which display the LA interference are identified and excluded for this purpose, the INR system is valid for monitoring oral anticoagulant treatment in patients with LA.
Collapse
|